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1 RESUME EN FRANÇAIS 
1.1 Les molécules du complexe majeur d’histocompatibilité classe II 
Les molécules du complexe majeur d’histocompatibilité de classe II (CMH-II) (1), aussi 
appelées antigènes leucocytaires humains (HLA), et antigènes Ia ou H2 chez la souris, sont 
codées par des gènes regroupés dans une seule région sur le chromosome 6 chez l’homme (Fig.3, 
p.20) et sur le chromosome 17 chez la souris. Il y a trois différents isotypes de molécules CMH-II 
chez l’homme (HLA-DR, HLA-DP et HLA-DQ) (2-5), et deux isotypes chez la souris (I-A et I-
E) (6, 7). Les molécules CMH-II jouent un rôle essentiel dans les réponses immunitaires 
spécifiques chez les vertébrés. Elles sont exprimées à la surface des cellules présentatrices 
d’antigènes pour présenter des peptides antigéniques aux lymphocytes T auxiliaires CD4+ (8, 9). 
Si un antigène est reconnu par le récepteur T d’un lymphocyte T, ce lymphocyte est activé et 
déclenche une réponse immunitaire spécifique, notamment en sécrétant des cytokines qui 
stimuleront la production d’anticorps par les cellules B et activeront les cellules T cytotoxiques 
CD8+.  
Les molécules CMH-II sont constituées par l’association non covalente de deux chaînes 
glycoprotéiques trans-membranaires, α et β (Fig.1, p.18; Fig.2, p.19). Les dimères αβ 
s’assemblent dans le réticulum endoplasmique et sont stabilisés par la chaîne invariante (10) 
(Fig.4, p.22). La chaîne invariante a deux fonctions: elle facilite le transport du réticulum 
endoplasmique à travers l’appareil de Golgi vers l’endosome et elle empêche la liaison précoce 
des peptides antigéniques aux molécules CMH-II. Dans l’endosome (11), la chaîne invariante est 
clivée par des protéases (12, 13). Un peptide de la chaine invariante, CLIP, reste attaché au site 
de liaison des molécules CMH-II. Catalysé par les molécules HLA-DM, CLIP est ensuite 
dissocié et remplacé par des peptides antigéniques, qui sont issus de la protéolyse des antigènes 
exogènes (14-16). Les complexes CMH-II sont finalement transporté à la surface cellulaire. 
 
 5 
1.2 L’expression des gènes CMH-II 
L’expression des gènes CMH-II est strictement régulée et est restreinte dans la plupart des 
situations physiologiques à quelques types cellulaires hautement spécialisés. Ceux-ci 
comprennent les cellules présentatrices d’antigènes, plus précisément les cellules dendritiques, 
les cellules B, les macrophages et les cellules T activées chez l’homme (17-21). De plus, un 
compartiment thymic spécialisé dans la sélection positive des lymphocytes T exprime les 
molécules CMH-II (22, 23). La plupart des autres types cellulaires n’expriment pas les molécules 
CMH-II de manière constitutive mais ces molécules peuvent être induites par l’interféron-γ (IFN-
γ) (17-21).  
Les expressions constitutive et inductible des gènes CMH-II sont principalement régulées au 
niveau transcriptionnel par des séquences régulatrices communes situées à proximité du site 
d’initiation de la transcription (18-21, 24-27). Elles sont composées de quatre éléments, la boîte 
W, la boîte X1, la boîte X2 et la boîte Y. La séquence, l’orientation, l’ordre et l’espacement de 
ces éléments sont conservées dans tous les gènes CMH-II ainsi qu’entre différentes espèces (18-
21, 24-27). La plus part des facteurs se liant à ces éléments ont pu être identifiés (Fig.6a, p.33). 
Le complexe RFX, composé de RFX5, RFXAP et RFXANK, se lie à la boîte X1 (28-33). La 
boîte X2 est contactée par le facteur X2BP (34, 35). Finalement, le facteur NF-Y, composé des 
trois sous-unités NF-YA, NF-YB et NF-YC se lie à la boîte Y (36). L’ensemble des trois facteurs 
RFX, X2BP et NF-Y fixé à l’ADN forme une plateforme qui sert de site de recrutement d’un 
coactivateur essentiel nommé CIITA (37, 38).  
CIITA et les trois sous-unités de RFX ont été isolés grâce à l’existence de patients atteints par 
le syndrome de déficience en molécules CMH-II (18, 25-27, 39-43). Cette maladie, appelée aussi 
BLS pour “Bare Lymphocyte Syndrome” est caractérisé par une absence d’expression des 
molécules CMH-II à la surface des cellules présentatrices d’antigène et des autres types 
cellulaires après stimulation par l’IFN-γ. Ceci entraîne une immunodéficience humorale et 
cellulaire sévère et abouti à la mort des patients au cours de l’enfance. L’absence globale 
d’expression des molécules CMH-II est la conséquence d’un défaut de transcription des gènes 
CMH-II. Elle concerne tous les gènes α et β codants pour HLA-DR, HLA-DP et HLA-DQ. Des 
expériences de fusion cellulaire ont permis de classer les patients dans quatre groupes de 
complémentation génétique distincts. Un gène différent est muté dans chaque groupe: MHC2TA 
 6 
dans le groupe A (38), RFXANK dans le groupe B (29, 30), RFX5 dans le groupe C (32) et 
RFXAP dans le groupe D (28) (Fig.5, p.28).  
RFX5 est la plus grande sous-unité du complexe RFX (32) (Fig.7C, p.35). Elle appartient à la 
famille RFX qui regroupe des protéines possédant toutes un domaine de liaison à l’ADN typique 
et spécifique de cette famille (44, 45). La structure du domaine de liaison à l’ADN à été définie 
pour un des membres de la famille RFX (RFX1) (46). Elle fait partie de la sous-famille “winged 
helix” qui elle fait partie de la famille hélice-boucle-hélice. La région N-terminale de la protéine 
RFX5 est impliquée dans l’interaction avec RFXANK et RFXAP (47, 48). En revanche, la partie 
C-terminale interagit avec CIITA et NF-Y (48).  
RFXANK porte son nom parce qu’il contient un domaine d’interaction entre protéines 
composé de quatre répétés ankyrine (29, 30) (Fig.7B, p.35). Ce domaine interagit avec CIITA, 
RFX5 et RFXAP. En plus, RFXANK touche l’ADN dans la partie 3’ de la boîte X1. 
RFXAP contient deux domaines d’activation potentiels, l’un riche en acides aminés acides et 
l’autre riche en résidus glutamine (28) (Fig.7D, p.35). Seul le domaine riche en résidus glutamine 
est essentiel pour la fonction de la protéine (47, 49). 
La liaison du complexe RFX à la boîte X1 est fortement stabilisée par l’interaction synergique 
avec les facteurs X2BP et NF-Y. L’ensemble ces trois facteurs RFX, X2BP et NF-Y liés à l’ADN 
forment l’« enhanceosome » (37). Ce complexe est extrêmement stable et occupe les promoteurs 
des gènes CMH-II avec une grande spécificité (50). L’absence du facteur RFX conduit à la perte 
de l’occupation du promoteur comme peut être observé dans les cellules de groupes de 
complémentation B à D (51-53) (Fig.6C, p.33). L’« enhanceosome » est essentiel mais pas 
suffisant pour l’expression des gènes CMH-II (Fig.6B, p.33). C’est le coactivateur CIITA qui est 
indispensable pour l’expression de manière constitutive et inductible (38, 54-60). Il détermine le 
niveau et la spécificité de l’expression des gènes CMH-II (18, 61). En effet, CIITA est exprimé 
uniquement dans les cellules exprimant les molécules CMH-II. La transfection des cellules qui 
n’expriment pas les molécules CMH-II avec du CIITA suffit pour activer l’expression des 
molécules CMH-II (55, 56, 62, 63). CIITA régule également l’expression des molécules CMH-II 
au cours de la différenciation des cellules B (56, 64). Dans les plasmocytes, le stade finale de 
différenciation des lymphocytes B, l’extinction des gènes CMH-II est la conséquence directe de 
la répression du gène MHC2TA. Enfin, CIITA régule aussi l’expression des molécules CMH-II 
de manière quantitative (65).  
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CIITA contient deux domaines riches en acides aminés acides et riches en résidus 
proline/sérine/thréonine dans la partie N-terminale, un domaine de liaison au GTP situé au centre 
de la protéine et des répétés riche en leucine situés dans la partie C-terminale (18, 61) (Fig.7A, 
p.35). Le contact avec l’« enhanceosome » se fait avec une grande partie de la région C-terminale 
par de multiples contacts protéine-protéine (37, 66). Cette région C-terminale peut fonctionner 
comme mutant dominant négatif (67-71). CIITA active la transcription par le biais du domaine 
d’activation dans sa partie N-terminale (68, 72, 73). Ce domaine contacte plusieurs facteurs 
généraux de la transcription (TAFII32, TAFII70, TFIIB), des facteurs impliqués dans l’élongation 
de la transcription (TFIIH, pTEFb) et des facteurs qui modifient la chromatine (CBP, pCAF) (69, 
74-77) (Fig.10, p.49). Pour son activité, CIITA s’associe avec soi-même (78-80). 
Le contrôle de l’expression des gènes CMH-II par CIITA se fait principalement au niveau de 
la transcription du gène MHC2TA (81). MHC2TA et son homologue Mhc2ta chez la souris sont 
localisés tous deux sur le chromosome 16. L’expression de MHC2TA est contrôlée par quatre 
promoteurs différents (82) (Fig.8, p.41). Les promoteurs pI, pIII et pIV sont conservés entre 
l’homme et la souris, le promoteur pII n’existe que chez l’homme et n’a pas été étudié en détail. 
Chaque promoteur précède un premier exon différent. Ce premier exon est épissé de manière 
alternative au deuxième exon commun. Ceci produit trois types de transcrits (type I, type III et 
type IV), chaqu’un possédant une extrémité différente en 5’ (82). Une protéine de 121 kD est 
traduite à partir d’un site d’initiation localisé dans le deuxième exon commun à tous les transcrits. 
Les transcrits de type I et III contiennent un site d’initiation de plus dans leur premier exon. 
L’utilisation de ces sites d’initiation alternatifs mène à des isoformes de 132 et 124 kD. Les 
extensions N-terminales uniques pour ces isoformes confèrent possiblement un aspect spécifique 
à ces protéines. L’isoforme de 132 kD par exemple semble avoir une demi-vie inférieure aux 
autres isoformes. 
Les différents types de CIITA sont exprimés dans différents types cellulaires (82). C’est le 
contrôle strict de la transcription du gène MHC2TA qui dicte l’expression restreinte et inductible 
des gènes CMH-II. Le promoteur pI de CIITA est exprimé spécifiquement dans les cellules 
dendritiques et dans les macrophages de souris induits par l’IFN-γ (82-85). La régulation de ce 
promoteur n’a pas encore été étudiée. Le promoteur pIII est utilisé dans les cellules B, dans les 
cellules T humaines activées et dans certains types de cellules dendritiques (82, 83, 86, 87). Une 
région promotrice de 320 paires de bases à été trouvée suffisante pour l’expression spécifique 
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(82, 86) (Fig.9B, p.44). Il contient des éléments liés par des facteurs de transcription inconnus. Le 
pIII peut être activé par l’IFN-γ dans certains types cellulaires par le biais d’un élément 
régulateur situé cinq kilobases en amont du site d’initiation de la transcription (88). L’activité du 
pIII est éteinte au cours de la différenciation terminale des cellules B (56, 64). Le facteur PRDI-
BF1 a été proposé d’agir comme répresseur du pIII dans les plasmocytes (89, 90). Le promoteur 
pIV est inductible par l’IFN-γ dans la plus part des types cellulaires (82, 88, 91-94). Un fragment 
promoteur de 300 paires de bases est suffisant pour la réponse à l’IFN-γ (82, 93, 94) (Fig.9C, 
p.44). Il contient un élément GAS, une boîte E et un site de liaison pour le facteur IRF-1. 
L’élément GAS et la boîte E sont liés par les facteurs STAT-1 et USF-1 de manière coopérative. 
L’expression du facteur IRF-1 dépend elle-même de l’induction par l’IFN-γ. L’expression de 
CIITA induite par l’IFN-γ peut être supprimée par plusieurs cytokines, notamment le TGF-β, 
l’IL-1, l’IL-4 et l’IL-10 (91, 95-97). Dans les souris auxquelles il manque le pIV CIITA les gènes 
CMH-II ne peuvent plus être induits par l’IFN-γ sauf par les cellules présentatrices d’antigène 
telles que la microglie ou les macrophages (85). C’est le pI qui est activé par l’IFN-γ dans ces 
cellules par un mécanisme inconnu (85). De plus, les cellules épithéliales du cortex thymique 
perdent aussi l’expression du CMH-II ce qui produit un déficit grave dans la sélection positive 
des lymphocytes T CD4+ (85). Le pIV est alors indispensable pour la réponse à l’IFN-γ dans 
toutes les cellules d’origine non-hematopoiëtiques. 
 
1.3 Les cellules dendritiques 
Les cellules dendritiques représentent des cellules présentatrices d’antigène uniques parce 
qu’elles sont capables d’activer des cellules T naïves (98-100). Elles existent en deux états de 
différentiation: immature et mature (Fig.11, p.66). En état immature, les cellules dendritiques 
sont localisées dans les tissus périphériques à l’interface avec l’environnement où elles absorbent 
des antigènes par micropinocytose, phagocytose et endocytose (101, 102). Les cellules 
dendritiques immatures expriment peu de molécules CMH-II à leur surface, mais elles les 
accumulent dans leur compartiment endosomale (103, 104). Des antigènes pathogénique et des 
cytokines inflammatoires sont capables d’activer les cellules dendritiques et d’induire leur 
programme de maturation (98). Ceci implique des changements majeurs dans la morphologie et 
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la fonction des cellules. Les cellules dendritiques induites à la maturation dégradent les antigènes 
qu’elles ont endocytosés auparavant et elles les chargent sur leurs molécules CMH-II qui sont 
stabilisées par cela (103, 104). Elles migrent dans les organes lymphatiques secondaires (105, 
106) pour présenter les peptides antigéniques dans le contexte des molécules CMH-II aux cellules 
T CD4+. Les cellules T CD4+ activées par l’engagement du recepteur T déclenchent une réponse 
immunitaire en activant des cellules T cytotoxiques et les cellules B (98).  
Les cellules dendritiques sont capables de présenter des antigènes endogènes et exogènes. Les 
antigènes endogènes sont dégradés par le protéasome et transférés par le transporteur TAP dans 
le réticulum endoplasmique (Fig.12, p.69). Dans ce compartiment ils sont chargés sur les 
molécules CMH classe I (CMH-I). Finalement, les complexes CMH-I-peptide sont transportés à 
la surface cellulaire. Pendant la maturation, le protéasome est modifié de telle manière qu’il 
favorise la génération de peptides qui s’adaptent bien au site de liaison des molécules CMH-I 
(107-109). Les antigènes exogènes sont dégradés dans le compartiment lysosomale et présentées 
par les molécules CMH-II (Fig.13, p.70). La formation des complexes CMH-II-peptide ne se fait 
qu’après l’induction de la maturation des cellules dendritiques (103, 110-113). Dans les cellules 
dendritiques immatures, les molécules CMH-II sont retenues dans le compartiment endosomale 
tardif et elles sont associées avec la chaîne invariante. La chaîne invariante est dégradée après 
l’induction de la maturation (110). Les peptides antigéniques peuvent s’attacher alors au site de 
liaison des molécules CMH-II et les complexe CMH-II-peptide sont transportés à la surface 
cellulaire. Les antigènes exogènes peuvent aussi être présentés par les molécules CMH-I et 
activer des cellules T CD8+ par le biais de la cross-présentation (114-116) (Fig.14, p.71). La 
cross-présentation permet l’initiation de réponses immunitaires cytotoxiques contre des antigènes 
qui ne sont pas synthétisés par les cellules dendritiques elles-mêmes. Cela implique donc le 
transfert d’antigène de cellules infectées aux cellules dendritiques.  
 
1.4 L’expression du gène MHC2TA dans les cellules dendritiques 
CMH-II est une molécule clé pour le fonctionnement des cellules dendritiques. Son expression 
et sa distribution cellulaire sont liées strictement à l’état de maturation dans ces cellules. Plusieurs 
études ont analysé le transport intracellulaire et le chargement des molécules CMH-II dans les 
cellules dendritiques (103, 111, 112, 117). Cependant, les mécanismes qui contrôlent les 
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changements dans la biosynthèse des molécules CMH-II durant la maturation des cellules 
dendritiques sont mal connus. Cet aspect a donc été étudié pendant cette thèse. Les résultats 
obtenus ont fait objet d’un article qui a été publié dans le « Journal of Experimental Medecine » 
(83). 
En utilisant des cellules dendritiques obtenues par différenciation de monocytes humains du 
sang péripherique, nous avons observé que le niveau des ARN messagers codant pour les 
protéines CMH-II diminue pendant la maturation induite par le lipopolysaccharide (LPS), jusqu’à 
23% de celui qui est observé dans les cellules dendritiques immatures (Fig.1C dans la 
publication, p.88[382]). Une évolution inverse a été observé pour les taux de protéines CMH-II 
présentées à la surface cellulaire durant cette même maturation par le LPS (Fig.1A et B dans la 
publication, p.88[382]).  
Pour comprendre l’origine de la diminution d’ARN messager CMH-II, nous avons analysé le 
coactivateur CIITA qui est essentiel pour la transcription des gènes CMH-II. Les trois isoformes 
de CIITA ont été détecté dans les cellules dendritiques immatures par immuno-précipitation 
(Fig.2C dans la publication, p.88[382]). Le taux de CIITA est réduit de huit fois pendant la 
maturation, et seule l’isoforme de 121 kD reste détectable dans les cellules matures. 
En ce qui concerne les ARN messagers de CIITA, nous avons observé que les cellules 
dendritiques immatures expriment des grandes quantités des transcrits de type I et de type III 
(Fig.3 dans la publication, p.xx). Le messager de type IV n’est guère exprimé dans ces cellules. 
Peu après l’induction de la maturation, le niveau des transcrits de type I et de type III est 
fortement réduit (Fig.3 dans la publication, p.88[384]). Un niveau basal à 5% du niveau de départ 
pour le type I et à 20% pour le type III est atteint après seulement 4 heures de stimulation avec le 
LPS. La réduction de l’expression des ARN messagers CIITA est considérablement plus rapide 
que celle des ARN messagers CMH-II. Cette différence de cinétique et au moins partiellement 
due à la différence de demi-vie des deux ARN messagers (plus de 24 heures pour CMH-II et ~1 
heure pour CIITA). Les donnés  sur l’extinction de CIITA pendant la maturation des cellules 
dendritiques humaines peuvent être étendues sur d’autres types de cellules dendritiques et sur 
d’autres espèces. Les cellules dendritiques dérivées de la moëlle osseuse de souris expriment 
l’ARN messager CIITA de type I et plus faiblement de type III et IV (Fig.4B dans la publication, 
p.88[385]). Avec l’induction de la maturation avec du LPS, cette expression est éteinte.  
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Afin de déterminer si l’extinction de CIITA observée dans les cellules dendritiques est 
spécifique à la stimulation par le LPS ou représente une conséquence de la maturation en général, 
nous avons mesuré les taux d’ARN messager CIITA dans les cellules dendritiques humaines 
après exposition au TNF-α, au CD40 ligand, à l’IFN-α, et après infection avec la souche 
bactérienne Salmonella typhimurium ou le virus de Sendai (Fig.5A dans la publication, 
p.88[385]). Tous ces stimuli ont induits une réduction profonde de CIITA malgré des cinétiques 
différentes. L’expression de CIITA a aussi été étudiée in vivo pendant le cours d’une maladie 
inflammatoire (Fig.4C et D dans la publication, p.88[385]). CIITA est réduite dans la rate de 
souris atteintes par l’encéphalite autoimmune expérimentale (EAE) aiguë comparé à des souris 
contrôles. Cette réduction est plus marquée quand l’analyse est faite avec des cellules 
dendritiques isolées à partir de la rate.  
Afin de déterminer si la réduction de l’ARN messager CIITA est due à une déstabilisation de 
l’ARN messager, nous avons comparé la stabilité des transcrits CIITA dans les cellules 
dendritiques immatures et matures. La demi-vie de l’ARN messager est très courte (~1 heure) 
dans les deux cas et aucune différence entre les deux n’a pu être mis en évidence (Fig.6A dans la 
publication, p.88[386]). Ces donnés suggèrent qu’un arrêt de la transcription est responsable de la 
diminution de l’ARN messager CIITA pendant la maturation des cellules dendritiques. Pour 
confirmer cette hypothèse nous avons mesuré la vitesse de transcription en quantifiant les 
transcrits naissants liés à la chromatine (Fig.6B dans la publication, p.88[386]). Nous avons 
détecté facilement les transcrits naissants de CIITA de type I et de type III dans les cellules 
dendritiques immatures. Dans les cellules dendritiques matures par contre, la synthèse de ces 
transcrits naissants est éteinte. Comme pour les taux d’ARN messager, la réduction est plus forte 
pour le type I que pour le type III de CIITA. En conclusion, ces résultats indiquent que la 
réduction de l’expression de CIITA est contrôlée par l’extinction de la transcription du gène 
MHC2TA.  
Des changements dans l’activité transcriptionelle sont souvent dus à des altérations 
d’occupation des séquences régulatrices ce qui peut être détecté par des expériences de « in vivo 
footprint ». Nous avons donc comparé l’occupation des promoteurs pI et pIII entre les cellules 
dendritiques immatures et matures (Fig.7 dans la publication, p.88[387]). La région proximale du 
pI et caractérisée par des protections sur les deux brins de l’ADN dans les cellules immatures. La 
maturation ne s’accompagne pas d’une modification de ces protections. La région proximale du 
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pIII est également occupée dans les cellules immatures et montre un profile similaire à celui 
observé dans les cellules B. Comme pour le pI, il n’y a aucun changement dans l’occupation du 
promoteur pendant la maturation.  
Trois arguments indiquent que les promoteurs pI et pIII du gène MHC2TA sont contrôlés par 
un mécanisme de répression globale, peut-être au niveau de la chromatine, pendant la maturation 
des cellules dendritiques. 1) pI et pIII sont espacés de plus que 12 kilobases. 2) Ils ne contiennent 
pas d’élément de régulation commun. 3) Les taux d’occupation du pI et pIII ne changent pas 
malgré l’extinction de ces promoteurs pendant la maturation. Au niveau de la chromatine, la 
répression de la transcription est souvent associée à la déacétylation des résidus lysine dans les 
queues des histones. Afin de savoir si ce mécanisme joue un rôle dans la répression du gène 
MHC2TA dans les cellules dendritiques, nous avons induit leur maturation avec du LPS en 
présence de TSA, un inhibiteur de déacétylases. TSA a effectivement empêché l’extinction de 
CIITA induit par le LPS (Fig.8A dans la publication, p.88[388]). Cette donnée suggère que la 
répression de CIITA est effectuée par un mécanisme qui mène à la déacétylation des histones 
associés à la région régulatrice du gène MHC2TA. Nous avons pu prouver cette hypothèse avec 
des expériences d’immuno-précipitation de la chromatine, utilisant des anticorps contre les 
histones H3 et H4 acétylés (Fig.8B dans la publication, p.88[388]). La région régulatrice du gène 
MHCIITA, qui s’étale sur plus que 12 kilobases, est acétylée entièrement dans les cellules 
dendritiques immatures. Après maturation par contre, cette acétylation est perdue. Le mécanisme 
qui à conduit l’extinction du gène MHC2TA implique donc la déacétylation d’une grande région 
régulatrice.  
 
1.5 L’analyse moléculaire du promoteur I de CIITA 
Les cellules dendritiques immatures expriment CIITA de type I et type III à des niveaux 
élevés. Les mécanismes qui contrôlent cette expression dans ces cellules est toujours inconnu. 
Nous avons donc étudié la régulation des promoteurs pI et pIII en détail. 
Les cellules dendritiques n’étant pas faciles à transfecter par des méthodes classiques, nous 
avons choisi un système de transduction utilisant des vecteurs lentiviraux. Ce système permet 
d’intégrer des transgènes de manière stable dans le génome des cellules qui ne se divisent pas. 
Les cellules dendritiques peuvent être transduites avec une efficacité de plus que 50% avec le 
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vecteur pWPTS qui code pour la GFP sous le contrôle du promoteur EF-1α (Fig.18A, p.94). Ce 
système de transduction n’engendre pas la maturation des cellules dendritiques (Fig.18B, p.94). 
Pour définir les régions fontionelles de pI, nous avons construit une série de délétions 
progressives en 5’ du promoteur, fusionées au gène GFP dans le vecteur pWPTS. Le fragment 
promoteur contenant 390 pairs de bases (pI-390) est suffisant pour une activité transcriptionelle 
(Fig.19, p.95). Les fragments plus longs par contre sont très faiblement ou pas du tout actifs. pI-
390 est un promoteur faible comparé à EF-1α (Fig.20, p.96). Son activité est aussi légèrement en 
dessous de l’activité du promoteur minimal de pIII, pIII-322. Par contre, le niveau d’expression 
de pI-390 est clairement plus élevé que le niveau basal d’un vecteur qui ne contient aucun 
promoteur (p0). pI-390 a été testé pour sa spécificité cellulaire. Il est exprimé uniquement dans 
les cellules dendritiques et des lignées promonocytiques U937 et THP1 (Fig.21, p.98). pI-390 
n’est donc pas strictement restreint aux cellules dendritiques mais semble être spécifique pour les 
cellules d’origine myéloide. En plus, le promoteur pIII-322 montre une activitée transcriptionelle 
élevée dans toutes les cellules testées, pas seulement dans les cellules B et dendritiques. Ces 
résultats sont inattendus et différent de ceux obtenus avec un système de tranfection transitoire 
(82). Aucune diminution de l’activité transcriptionelle de pI-390 et pIII-322 n’a pu être observée 
pendant la maturation des cellules dendritiques (Fig.22, p.99), malgré la forte répression des 
promoteurs pI et pIII endogènes. Les éléments régulateurs impliqués dans cette répression sont 
probablement localisés en dehors des séquences promotrices minimales et loin des sites 
d’initiation de la transcription. Cette hypothèse est en accord avec le mécanisme global qui est 
résponsable de l’extinction de CIITA pendant la maturation des cellules dendritiques.  
 
1.6 Conclusions 
Les cellules dendritiques immatures synthétisent des molécules CMH-II en grande quantité, 
mais ce n’est qu’après la maturation que ces molécules sont chargées et transportées à la surface. 
L’expression de surface élevée soutient les cellules dendritiques matures dans leur rôle de 
présentation des peptides antigéniques aux cellules T CD4+. A l’inverse de l’augmentation des 
molécules CMH-II à la surface, la biosynthèse de CMH-II est réduite pendant la maturation. Cet 
arrêt de synthèse garantit que les complexes CMH-II-peptide ne sont pas dilués et remplacés par 
de nouveaux complexes produits pendant la maturation. Ceci est cohérent avec le fait que les 
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cellules matures perdent leur capacité d’intérnaliser des antigènes. La réduction de la synthèse 
des molécules CMH-II pendant la maturation est due à l’extinction du gène MHC2TA. Cette 
réduction est observée dans les cellules dendritiques de l’homme et de la souris en réponse à 
toute une série de stimulis, et même chez des souris souffrant d’une maladie inflammatoire. Les 
deux promoteurs pI et pIII sont réprimés de manière coordinée pendant la maturation des cellules 
dendritiques. pI et pIII sont distants de 12 kb et ils ne contiennent aucune séquence régulatrice en 
commun. Ces données suggèrent que l’extinction est médiée par un mécanisme régulateur global 
qui concerne tous les promoteurs du gène MHC2TA simultanément. En effet, ce mécanisme 
implique la déacétylation de la région promotrice entière du gène MHC2TA. C’est donc un 
remaniement de la chromatine et non pas une répression restreinte aux promoteurs individuels qui 
mène à l’extinction de MHC2TA pendant la maturation des cellules dendritiques. 
Le mécanisme de la régulation de pI n’a pas été étudié pendant de nombreuses années par 
manque d’une lignée cellulaire qui exprime ce promoteur et qui se comporte comme des cellules 
dendritiques primaires. Les cellules dendritiques primaires ne peuvent pas être transfectées par 
des méthodes classiques. C’est grace à un système de transduction utilisant des vecteurs 
lentiviraux que nous avons pu réaliser l’analyse de pI dans ces cellules. Un fragment promoteur 
de 390 pairs de bases est suffisant pour dirigé l’expression dans les cellules dendritiques. Son 
activité est restreinte aux cellules d’origine myéloide. En plus, l’état de maturation des cellules 
n’influence pas l’expression de pI-390. Ces charactéristiques rendent le promoteur pI très 
intéressant pour des stratégies d’immunothérapie ou de vaccination.  
 
En conclusion, ce travail de thèse a permis de mieux comprendre les mécanismes qui 
contrôlent l’expression de CMH-II dans les cellules dendritiques immatures et matures. En 
particulier, il éclaircit le rôle de CIITA, le régulateur clé des gènes CMH-II, pendant la 
maturation. En plus, la régulation du promoteur de CIITA qui est spécifique pour les cellules 
dendritiques a été examinée. 
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2 INTRODUCTION 
2.1 MHCII 
Major histocompatibility complex (MHC) molecules, also called human leukocyte antigens 
(HLA) in human and Ia or H-2 antigens in mouse, were first detected as cell surface antigens that 
varied between different strains of mice and that were encoded by several genes responsible for 
the rejection of transplanted tissues (118). Later, the genes controlling immune responses in 
transplantation and specificity of antigen recognition by T cells were assigned to the same MHC 
loci (119-121). Since then, much has been learned about the structure, diversity and function of 
MHC molecules. 
 
2.1.1 MHCI versus MHCII molecules 
There are two classes of MHC molecules, class I (MHCI) and class II (MHCII). MHCI and 
MHCII molecules are both transmembrane glycoproteins belonging to the immunoglobulin 
supergene family, and their structures are very similar. However, their polypeptide chain 
composition, patterns of expression and functions in the immune system are very different 
(Fig.1).  
MHCI molecules are composed of a transmembrane α chain associated non-covalently with 
the β2-microglobulin (β2m) chain. They are expressed on essentially all nucleated cell types. 
MHCI molecules are specialized for the presentation of peptides derived from endogenous 
proteins to the T cell receptor (TCR) of CD8+ T cells.  
MHCII molecules are composed of two non-covalently linked transmembrane chains, called α 
and β. In contrast to the ubiquitous expression of MHCI, MHCII molecules are expressed only on 
a subset of cells. They are specialized for the presentation of extracellular antigens to the TCR of 
CD4+ T cells. 
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Figure 1. MHCI and MHCII molecules. A. Interaction of a peptide-loaded MHCI molecule on any cell type with 
the TCR of a CD8+ T cell. B. Interaction of a peptide-loaded MHCII molecule on an antigen presenting cell (APC) 
with the TCR of a CD4+ T cell. 
 
2.1.2 The role of MHCII molecules in the immune response 
MHCII is one of the key molecules for the development of a specific immune response to a 
pathogen (8, 9). MHCII-peptide complexes displayed at the surface of antigen presenting cells 
(APCs) are recognized by the TCR and the CD4 co-receptor on CD4+ T cells. This triggers 
activation and proliferation of the T cells and thus elicits an immune response specific for the 
antigen from which the MHCII bound peptides were derived.  
MHCII molecules are also crucial for selection and maturation of CD4+ T cells in the thymus. 
Positive selection, which ensures the survival of T cells that carry TCRs capable of recognizing 
self-MHC molecules, is driven by MHCII positive epithelial cells in the thymic cortex (cTECs) 
(23). On the other hand, elimination of autoreactive T cells by negative selection is driven by 
MHCII positive thymic dendritic cells in the medulla (122, 123). 
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2.1.3 The structure of MHCII molecules 
MHCII molecules belong to the immunoglobulin gene family. They are heterodimeric 
glycoproteins consisting of two non-covalently linked transmembrane chains called α (33 kD) 
and β (29 kD). The difference in size of the two chains is mainly attributed to differences in N-
linked glycosylation. The α and β chains have the same overall conformation, each consisting of 
two extracellular domains, α1 and α2, and β1 and β2, respectively. The membrane-distal 
domains combine to form a single peptide binding groove composed of two antiparallel α-helical 
loops supported by a platform of eight antiparallel β strands (124) (Fig.2). The groove is capable 
of binding a wide range of peptides. Peptides binding to MHCII molecules are at least 13 amino 
acids long and can be much longer. Their N- and C-termini may extend beyond the ends of the 
groove. The peptides are held in the peptide-binding groove both by peptide side chains (anchor 
positions) that protrude into polymorphic pockets lined by residues that vary between MHCII 
molecules, and by interactions between the peptide backbone and the side chains of residues that 
are conserved in all MHCII peptide-binding grooves. 
 
 
 
Figure 2. Three-dimensional structure of MHCII. A. X-ray structure of HLA-DR1 with the α chain in blue and 
the β chain in red. B. Complex between HLA-DR3 and the CLIP peptide (in red). CLIP and antigenic peptides bind 
in an almost identical manner (125). 
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 2.1.4 The diversity of MHCII genes and their genomic organization 
Three classical MHCII molecules exist in man: HLA-DP (3), HLA-DQ (4) and HLA-DR (2, 
5). Mice only express proteins orthologous to the last two, I-A (6) and I-E (7), respectively. In 
addition, both species encode so-called nonclassical molecules, namely HLA-DM (126) and 
HLA-DO (127, 128) in human, and H2-M (129) and H2-O (130) in mouse. The α and β chains of 
each MHCII molecule are encoded by separate genes in the class II region of the MHC (1) 
(Fig.3). The human MHC is located on the short arm of chromosome 6, while the mouse MHC is 
situated on chromosome 17. In all cases, except for HLA-DO, the pairs of genes are encoded 
adjacently. Remarkably, the class II region of the MHC is full of pseudogenes. These may be 
involved in generating new alleles by gene conversion. The class II region appears to have been 
subjected to several duplications generating novel gene family members, which have then 
diverged into new functions. The duplications must have taken place at several different periods 
throughout evolution of the class II gene family. HLA-DM, for instance, is only weakly related to 
other class II sequences, thus resulting from an ancient gene duplication, whereas HLA-DO 
shares about 60% identity with HLA-DR, thus representing a more recent duplication.  
The class II region of the human and mouse MHC harbors a small number of genes involved 
in antigen presentation by MHCI. These encode the TAP transporter (TAP1, TAP2) as well as 
subunits of the immunoproteasome (LMP2, LMP7). In addition, many loci exist in the MHC that 
do not play any role in the immune system (131). 
 
 
 
Figure 3. The class II region of the human MHC (131). The class II region of the human MHC extends over 1’000 
kb from its centromeric to telomeric end (from right to left) of the short arm of chromosome 6. The approximate 
positions and transcriptional orientations of all identified genes (in red) and pseudogenes (in gray) are shown. The 
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expressed immune loci are marked with an asterix. The classical class II region is highlighted by a blue background, 
the extended class II region by a pink background.  
 
2.1.5 Polymorphism 
Classical MHCII genes exhibit an extraordinary degree of allelic polymorphism. There are 
more than 200 alleles of some MHCII loci. The polymorphic residues are primarily those that 
interact with the TCR and determine the shape of the peptide-binding groove. They consequently 
influence both the recognition of the MHCII-peptide complex by the TCR and the peptide 
specificities of different MHCII alleles. In addition, MHCII polymorphism contributes to the 
susceptibility to autoimmune diseases, has important functional implications in clinical organ and 
bone marrow transplantation, and provides a very useful set of markers for the field of human 
population genetics.  
The nonclassical class II molecules are relatively invariant. Some alleles of both HLA-DM 
and HLA-DO have been described, but these vary by small numbers of amino acids and, so far, 
have no known functional significance. In addition, the human DRα chain has also been shown 
to be monomorphic. 
 
2.1.6 Formation of MHCII-peptide complexes 
MHCII molecules are synthesized in the endoplasmatic reticulum (ER). In the ER, three α/β 
MHCII dimers associate with a trimer of invariant chains (Ii) (10) (Fig.4). A number of 
functional consequences of the association of MHCII with Ii trimers are known. First, Ii serves as 
a scaffold to facilitate protein folding and assembly of MHCII molecules. Second, Ii occupies the 
class II peptide binding cleft, thereby blocking premature MHCII-peptide association. Third, Ii-
association is critical for normal intracellular trafficking of MHCII molecules, since MHCII 
molecules synthesized in the absence of Ii aggregate and do not exit the ER (132, 133). The Ii-
associated MHCII molecules exit the ER and are transported via the Golgi to the endocytic 
pathway, more precisely to a late endosomal antigen-processing compartment called MIIC (11). 
This process is regulated by two di-leucine endocytic signals present in the Ii cytosolic domain 
(134). Once in the MIIC, the Ii-associated MHCII complexes meet an acidic, protease rich 
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environment, where the Ii chain is degraded by the stepwise action of aspartyl proteases and 
cathepsins (12, 13). This generates the intermediates Iip23 and Iip10 and finally CLIP (class II 
associated Ii peptide). CLIP is derived from Ii amino acid residues 81-104 and binds to the 
antigen-binding groove of MHCII molecules (Fig.2). MHCII molecules then become competent 
to bind antigenic peptides that come from the degradation of exogenous proteins. Efficient 
exchange of CLIP for antigenic peptides is catalyzed by HLA-DM. HLA-DM binds transiently to 
MHCII-CLIP and stabilizes an intermediate state where CLIP is released, allowing other peptides 
to bind (14-16). HLA-DM dependent peptide loading occurs within the context of other 
associated molecules, such as HLA-DO (135, 136) and tetraspanins (137). HLA-DO is a B-cell 
specific and pH-dependent modulator of HLA-DM. It effectively blocks HLA-DM function at the 
endosomal pH, while allowing HLA-DM action at the more acidic pH of the MIICs (135, 138, 
139). In this way, HLA-DO action may skew the class II-peptide loading process toward acidic 
compartments. Once stable complexes of MHCII and antigenic peptides are formed, they are 
released from HLA-DM and transported to the cell surface.  
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Figure 4. Formation of MHCII-peptide complexes. Newly synthesized αβ dimers associate with Ii in the ER and 
are transported through the Golgi apparatus. The Ii-associated MHCII molecules are diverted from the constitutive 
seccretory pathway into the endocytic pathway. This can occur following a direct pathway from the Golgi to a 
specialized antigen-processing compartment (MIIC) or indirectly after transit through to the cell surface and 
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endocytosis. In the MIIC, Ii is degraded leaving behind the CLIP peptide. Exogenous antigens are derived from 
proteins that are endocytosed and processed by proteases. The peptides bind to MHCII molecules replacing CLIP in 
an HLA-DM dependent manner, and the MHCII-peptide complexes are then transported to the plasma membrane.  
 
2.1.7 Expression of MHCII molecules 
The pattern of MHCII expression is complex and very tightly regulated. Under normal 
conditions, most classical and non-classical MHCII genes are regulated in a coordinated fashion. 
Two general modes of MHCII expression can be distinguished: constitutive and inducible (17-
21).  
Constitutive MHCII expression is largely restricted to APCs, such as dendritic cells (DCs), B 
cells and macrophages. In addition, certain epithelial and endothelial cells, most importantly 
cTECs, and activated human T cells express MHCII constitutively. Expression within an APC 
lineage can vary dramatically as a function of developmental stage. For instance, immature pre-B 
cells are MHCII negative, but become positive as they mature into B cells. Upon terminal 
differentiation of B cells into plasmocytes, MHCII expression is silenced again. In immature 
DCs, only few MHCII molecules are displayed at the cell surface, but they are upregulated 
dramatically with the induction of DC maturation. In many MHCII-negative cell types, MHCII 
expression can be induced by various stimuli of which IFN-γ is the most potent and well known. 
Constitutive and inducible MHCII expression can be modulated by a large number of stimuli (17-
21). For example, IL-4, IL-10 and IL-13 enhance MHCII expression in B cells, whereas 
glucocorticoids and prostaglandins diminish it. IFN-γ induced MHCII expression is positively 
regulated by IL-4 and TNF-α, but negatively by TGF-β, IL-10, CSF-1, and type 1 interferons.  
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2.2 Regulation of MHCII expression 
The molecular mechanisms regulating MHCII expression are the subject of a review that has 
been accepted for publication. 
 
“CIITA and the MHCII enhanceosome in the regulation of MHCII expression” 
Salomé Landmann, Jean-Marc Waldburger, Krzysztof Masternak, Annick Mühlethaler-Mottet 
and Walter Reith. 
Current Genomics (2002), in press. 
 
Summary 
MHCII molecules direct the development, activation and homeostasis of CD4+ T cells. Given 
these key functions it is not surprising that the absence of MHCII expression results in a severe 
primary immunodeficiency disease called MHCII deficiency or the Bare Lymphocyte syndrome 
(BLS). The genetic defects responsible for BLS lie in genes encoding transcription factors 
required for MHCII expression. Four different MHCII regulatory genes encoding RFXANK, 
RFX5, RFXAP and CIITA have been identified. The first three are subunits of RFX, a 
ubiquitously expressed factor that binds cooperatively with other proteins to MHCII and related 
promoters to form a highly stable macromolecular nucleoprotein complex referred to as the 
MHCII enhanceosome. This enhanceosome serves as a landing pad for the MHCII transactivator 
CIITA. CIITA is a non-DNA binding coactivator that serves as the master control factor for 
MHCII expression. The highly regulated expression pattern of CIITA ultimately dictates the cells 
type specificity, induction and level of MHCII expression. The enhanceosome and CIITA 
collaborate in activating transcription by promoting histone hyperacetylation and by recruiting 
components of the general transcription machinery.  
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CIITA AND THE MHCII ENHANCEOSOME IN THE REGULATION OF MHCII 
EXPRESSION 
 
S.Landmann, J.-M..Waldburger, K.Masternak, A.Muhlethaler-Mottet and W.Reith 
Department of Genetics and Microbiology, University of Geneva Medical School 
 
Abstract 
Major histocompatibility complex class II (MHCII) molecules direct the development, 
activation and homeostasis of CD4+ T cells. Given these key functions it is not surprising that the 
absence of MHCII expression results in a severe primary immunodeficiency disease called 
MHCII deficiency or the Bare Lymphocyte Syndrome (BLS). The genetic defects responsible for 
BLS lie in genes encoding transcription factors required for MHCII expression. Four different 
MHCII regulatory genes encoding RFXANK, RFX5, RFXAP and CIITA have been identified. 
The first three are subunits of RFX, a ubiquitously expressed factor that binds cooperatively with 
other proteins to MHCII and related promoters to form a highly stable macromolecular 
nucleoprotein complex referred to as the MHCII enhanceosome. This enhanceosome serves as a 
landing pad for the MHCII transactivator CIITA. CIITA is a non-DNA binding coactivator that 
serves as the master control factor for MHCII expression. The highly regulated expression pattern 
of CIITA ultimately dictates the cell type specificity, induction and level of MHCII expression. 
The enhanceosome and CIITA collaborate in activating transcription by promoting histone 
hyperacetylation and by recruiting components of the general transcription machinery. In this 
review we summarize what is known about the molecular basis of BLS and what this has taught 
us about the mechanisms regulating transcription of MHCII and related genes. Particular 
attention is devoted to the structure, function and mode of action of the MHCII enhanceosome 
and CIITA. In addition, we focus on the highly regulated and cell type specific expression of 
CIITA. 
 
Introduction 
MHCII molecules are heterodimeric (α chain – β chain) transmembrane glycoproteins 
displayed at the surface of specialized cells of the immune system. In humans, there are three 
MHCII isotypes designated HLA-DR, HLA-DQ and HLA-DP. All three isotypes serve the same 
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function, namely the presentation of peptides to the TCR of CD4+ T helper cells. This is crucial 
for numerous aspects of the adaptive immune system, including the selection, activation and 
survival of CD4+ T cells [1,2]. Two general modes of MHCII expression exist: constitutive and 
inducible [3-9]. Constitutive expression is the hallmark of professional APCs. These include B 
lymphocytes, cells of the monocyte/macrophage lineage and DCs. cTECs and activated human T 
cells are also MHCII positive. Most other cell types do usually not express MHCII molecules but 
can be induced to do so in response to various stimuli of which IFN-γ is the most potent and well 
known. Both constitutive and induced MHCII expression can be further modulated by additional 
signals. Constitutive expression in B cells and DCs is for instance regulated as a function of 
developmental stage. MHCII expression is extinguished upon differentiation of B cells into 
plasmocytes. In DCs, maturation is accompanied by an increase in cell surface MHCII 
expression. Finally, IFN-γ induced expression can be modified by various stimuli. For example 
TGF-β, IFN-α and IL-4 inhibit induction of MHCII by IFN-γ.  
The central importance of correctly regulated MHCII expression is underlined by the fact that 
deregulation of this expression leads to disease. Aberrant or inappropriate MHCII expression has 
been incriminated in the pathology of certain CD4+ T cell-mediated autoimmune diseases [10]. 
On the other hand, the lack of MHCII expression severely cripples the immune system and leads 
to a life-threatening immunodeficiency syndrome [7-9,11-14].A detailed understanding of the 
molecular mechanisms that control MHCII expression thus represents an important contribution 
to both molecular immunology and immunopathology. 
 
The Bare Lymphocyte Syndrome 
A disease resulting from the absence of MHCII expression 
The absence of MHCII expression is the cause of a primary immunodeficiency syndrome 
called the Bare Lymphocyte Syndrome (BLS) [7-9,11-16]. BLS is a rare autosomal recessive 
disease and has a high incidence of consanguinity [17]. Since its first description in the late 1970s 
and early 1980s [18-23], only about 70 patients from 50 unrelated families have been reported. 
Detailed descriptions of the clinical and immunopathological characteristics of the disease 
have been published previously [11-13,24], and we will thus restrict ourselves here to a brief 
description of the most salient features. Symptoms start within the first year of life, and comprise 
primarily severe and repeated infections, protracted diarrhea, malabsorption, and failure to thrive. 
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The patients are particularly prone to infections of the gastrointestinal, pulmonary, upper 
respiratory and urinary tracts. The type of infectious agent is not pathognomic, and they can be of 
viral, bacterial, fungal or protozoan origin. Few children reach puberty. The majority dies 
between the age of 6 months and 5 years.  
The mainstay of diagnosis is the absence of constitutive and inducible expression of MHCII 
genes [11-14,24]. Moreover, expression of the HLA-DM genes is suppressed and expression of 
the invariant chain Ii is reduced [25,26]. The level of MHCI expression is also reduced to a 
variable extent in many BLS patients. However, the clinical and immunopathological 
manifestations of the disease are thought to result mainly from the defect in MHCII expression. 
Total numbers of circulating T and B lymphocytes are normal. However, in the majority of 
patients, the ratio of CD4+ to CD8+ T cells is reduced [11-13,24]. There is a reduction in the 
absolute number of CD4+ T cells and a concomitant increase in CD8+ T cells. This presumably 
reflects a deficiency in positive selection of CD4+ thymocytes, and is a consequence of the lack 
of MHCII expression on cTECs. Albeit reduced in numbers, the remaining CD4+ T cells in the 
patients do not exhibit major phenotypic abnormalities [27]. Although the residual CD4+ T cells 
in BLS patients may be functional, the absence of MHCII on APCs and the resulting inability to 
present antigens to CD4+ T cells leads to a severely compromised immune system [11-13,24]. 
Humoral immune responses to immunizations and to infectious agents are absent or strongly 
reduced. Cellular immune responses are also defective. 
In all patients, the lack of cell surface MHCII expression is a consequence of the fact that the 
corresponding genes are not transcribed [28]. Several lines of evidence have shown that the 
defects responsible for the disease do not reside in the MHCII locus itself, but lie in transacting 
regulatory genes controlling MHCII expression [12,17,29-34] (Fig.5).  
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Figure 5. BLS is a disease of gene regulation. The MHC2TA, RFXANK, RFX5 and RFXAP genes are mutated in 
the BLS complementation groups A, B, C and D, respectively. These four genes are essential for the expression of 
MHCII and related genes. These include the genes coding for HLA-DR, HLA-DP, HLA-DQ, HLA-DM, HLA-DO 
and the invariant chain Ii. 
 
Genetic heterogeneity in the cause of BLS 
BLS is considered to be a single phenotypic entity. However, the disease is genetically 
heterogeneous [17,30-32]. Four different BLS complementation groups (A to D), reflecting the 
existence of mutations in four distinct MHCII regulatory genes, have been defined [17,30-32]. 
The regulatory gene affected in each complementation group has now been identified. The four 
affected genes are called MHC2TA (group A), RFXANK (group B), RFX5 (group C) and RFXAP 
(group D) [35-39]. The patient-derived cell lines, together with several experimentally generated 
MHCII negative mutants, have thus allowed the isolation and characterization of four key MHCII 
specific transcription factors and have hence constituted a unique tool for the investigation of the 
regulation of MHCII gene expression. 
The nature of the genetic defect does not correlate with the course of the disease. There is no 
obvious genotype-phenotype relationship between the regulatory gene that is affected and either 
the immunological features, the precise clinical picture, the severity of the disease or the 
prognosis. Despite the genetic heterogeneity, BLS is therefore clinically homogenous.  
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Certain BLS patients display only mild symptoms or are even assymptomatic [40]. A patient 
exhibiting a very late onset of the disease (in his late twenties) has also been described [41]. 
Interestingly, in contrast to the situation observed in the majority of classical patients, the 
mutations identified in late onset patients do not destabilize the affected factor [40]. As the other 
"classical" patients, these individuals completely lack MHCII expression or display only very low 
residual levels of MHCII molecules at the surface of their cells. Moreover, they have been 
assigned to one of the four known complementation groups. It is thus clear, that some patients 
display an attenuated clinical phenotype despite their profound defect in MHCII expression. This 
has two important implications. First, there are likely to be additional - as yet undefined - 
"modifier" loci that have a major impact on the severity and course of the disease. Second, the 
frequency of the inherited MHCII deficiency disease is likely to be underestimated. 
 
Lessons from mouse models of BLS 
There are no spontaneous animal models for BLS. However, identification of the genes 
affected in the human disease has permitted the generation of two mouse models. Knockout mice 
reproducing the molecular defects of BLS patients in groups A and C have been constructed by 
deletion of the Mhc2ta and Rfx5 genes [42-45]. The major immunopathological characteristics of 
the human disease are reproduced in these mice. Both models show a strong reduction of 
constitutive MHCII expression on professional APCs (B cells, DCs and macrophages). IFN-γ 
induced expression is also abolished. As in humans, this loss of MHCII expression results in a 
severely compromised immune system.  
The absence of CD4+ T cell-dependent immune responses in the mouse models is a 
consequence both of the inability to present antigen via MHCII molecules and of a severe CD4+ 
T cell deficiency. The CD4+ T cell population in Mhc2ta and Rfx5 knockout mice is decreased 
over tenfold [42-45]. This strong reduction is a consequence of severely impaired positive 
selection, which results from an essentially complete loss of MHCII expression on epithelial cells 
in the thymus. Surprisingly, the reduction in CD4+ T cells in BLS patients is rarely greater than 
two to three fold [11,12] and is thus considerably less pronounced than in the knockout mice. At 
least two explanations could account for this difference between the human and mouse 
phenotypes. First, the relatively mild decrease in peripheral CD4+ T cells in BLS patients 
suggests that positive selection may be compromised only partially. This could be explained by 
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the retention of a sufficient level of residual MHCII expression in the thymus. Whether or not 
this is indeed the case remains to be determined because MHCII expression patterns in the 
thymus have only been examined in a few isolated cases [46]. It may be relevant that residual 
expression of MHCII in the thymus has been observed in one patient [46]. A second 
interpretation could be that the CD4+ T cells in BLS patients have escaped the normal selection 
processes in the thymus. They may for example have been selected on ligands other than MHCII 
molecules. In MHCII deficient mice, for instance, a large proportion of the residual CD4+ cells 
are CD1-restricted [47]. Such alternative selection pathways could be more prominent in BLS 
patients. Interestingly, an analysis of the T cell repertoire in BLS patients has revealed minor 
alterations, suggesting that the CD4+ T cells in these patients may indeed have been subjected to 
an unusual selection mechanism [48,49].  
Both the Mhc2ta-/- and Rfx5-/- mice exhibit residual MHCII expression in certain tissues and 
cell types. The precise pattern of residual expression differs between the two mice. This implies 
that specific cellular compartments possess alternative pathways for MHCII expression that can 
partially bypass the strict requirement for RFX5 and/or CIITA [42-44]. Rfx5-/- mice retain 
relatively strong MHCII expression in the thymic medulla and significant, albeit weaker, 
expression on a fraction of splenic and bone marrow derived dendritic cells. Low MHCII 
expression is also induced on B cells from Rfx5-/- mice following activation in vitro with 
lipopolysaccharide (LPS) and/or IL-4. In contrast, residual MHCII expression in the Mhc2ta-/- 
mice is mainly restricted to DCs in the paracortex of lymph nodes, B cells in the germinal centers 
of the spleen and lymph nodes, and a subset of cTECs. This difference in the residual expression 
pattern is surprising because the human disease is considered to be phenotypically homogeneous. 
Leaky expression has been observed in cells from certain BLS patients, but no characteristic 
residual expression pattern distinguishing RFX5 deficient patients from those with defects in 
CIITA have been described [11,12,24]. This discrepancy may reflect species-specific differences 
in the dependence on the two MHCII regulatory genes. However, it is also possible that the 
phenotypic differences observed in the mouse system exist in the human disease as well, but have 
escaped attention until now. Due to the rarity and severity of the disease, only relatively few 
patients from defined complementation groups have been studied in detail with respect to residual 
MHCII expression.  
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Therapeutic strategies 
Carrier detection and prenatal diagnosis for BLS 
Considering the rarity of BLS, prenatal/postnatal diagnosis or carrier detection on a 
population-wide scale is not justified. On the other hand, these procedures could be valuable if 
restricted to families that already have affected children, or when a consanguineous union is 
envisaged in a high risk population. Previously, prenatal diagnosis relied on the analysis of 
MHCII expression on fetal leukocytes obtained by an umbilical vein puncture [50]. With our 
current knowledge of the molecular defects in BLS, mutated alleles of MHC2TA, RFXANK, 
RFX5 or RFXAP can now be screened for by using flanking polymorphic markers or by a direct 
search for known mutations. The greater sensitivity of these molecular techniques will allow the 
development of prenatal diagnosis by less invasive procedures, such as choriocentesis or 
amniocentesis. In addition, thanks to these techniques healthy carriers can now be identified 
rapidly and given accurate genetic counseling.  
 
Gene therapy for BLS 
Allogeneic bone marrow transplantation (BMT) is currently the only curative treatment 
available for BLS [51]. A cord blood transplantation from an HLA-identical sibling has also been 
successful in the case of one patient with an allogeneic BMT graft failure [52]. The overall 
success rate of BMT in this disease has been reported to be relatively poor as compared to other 
immunodeficiency syndromes. This does not appear to be a peculiarity resulting from the 
immunological phenotype of BLS. Instead, it is likely to be due largely to other problems, such 
as the fact that the disease is often diagnosed at a rather late age, when recurrent illness will have 
compromised the success of BMT [51,53]. Now that the affected genes have been identified, 
gene therapy becomes a potential alternative to BMT. Introduction of the wild type MHC2TA, 
RFXANK, RFX5 or RFXAP genes into hematopoietic stem cells (HSCs) of BLS patients in 
complementation groups A, B, C or D, respectively, would represent a logical therapeutic 
strategy. The Mhc2ta and Rfx5 knockout mice will be valuable for developing gene therapy for 
BLS. 
Abnormal selection of CD4+ T cells, resulting from the absence of MHCII expression on 
thymic epithelial cells, is unlikely to represent an obstacle for gene therapy in BLS. The fact that 
classical BMT can cure BLS suggests that restoring MHCII expression on thymic epithelial cells 
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is not essential. This is consistent with the fact that successful BMT does not require a functional 
thymus; the T cell pool can be reconstituted through peripheral expansion of passenger donor T 
cells present in the graft [54]. In this respect it is also worth mentioning that in a MHCI deficient 
mouse model, MHCI expression on bone marrow derived cells was found to be sufficient to 
compensate for the defect in thymic selection of CD8+ T cells [55]. 
One potential concern is that the therapeutic transgene could induce ectopic or non-
physiological levels of MHCII expression, which could have deleterious consequences and result 
in tissue destruction or autoimmunity. This is unlikely to be a major problem in the case of RFX5, 
RFXANK and RFXAP, which are expressed ubiquitously in all cell types. The MHC2TA gene, on 
the other hand, is tightly regulated and it will be difficult to obtain a pattern of transgene 
expression that mimics that of the endogenous gene. 
 
RFX and CIITA as targets for novel immunomodulators 
MHCII expression is completely lost or severely reduced in BLS patients. This is also the case 
in most cell types in the two mouse models for the human disease. This suggests that CIITA, 
RFXANK, RFX5 and RFXAP are essential and that no bypass or alternative pathways can 
compensate efficiently for their absence. Moreover, no other major systems are as critically 
dependent on these regulatory factors. These features imply that inhibitors specific for CIITA, 
RFXANK, RFXAP and RFX5 should induce a highly selective downregulation of MHCII 
expression. CIITA, RFXANK, RFXAP and RFX5 may thus represent prime targets for novel 
immunomodulatory drugs having wide applications in situations such as organ transplantation 
and autoimmune diseases, where inhibition of MHCII expression might be desirable or 
beneficial. 
 
Tumor immunotherapy.  
Tumors frequently have reduced immunogenicity because they lack MHCII molecules. The 
immunogenicity and rejection of such tumors can be increased by the expression of MHCII alone 
or in combination with costimulatory molecules [56-58]. This has of course raised hopes that the 
introduction of CIITA to activate MHCII expression might enhance tumor immunogenicity and 
thus contribute to the success of tumor therapy. Experiments of this type have been performed 
[59], although with limited success so far. 
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 Regulation of MHCII expression 
Overview 
MHCII expression is regulated primarily at the level of transcription [3-9,14]. The promoter 
proximal region of MHCII and related genes contains the conserved cis-regulatory elements 
referred to as W (or S), X, X2 and Y "boxes" (Fig.6). These elements are highly conserved in 
their sequence, orientation, order and spacing relative to each other, and they function together as 
a single composite enhancer unit [3-9,14].  
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Figure 6. The promoter proximal region of MHCII and related genes is bound by the MHCII enhanceosome, 
which serves as a landing pad for the recruitment of CIITA. a) The promoter proximal regions of MHCII and 
related genes contain the conserved W, X, X2 and Y cis-regulatory elements. These elements are bound by the RFX, 
X2BP and NF-Y complexes and a putative W binding protein. These factors function together as a composite unit 
called the MHCII enhanceosome. The latter recruits the master regulator CIITA to the promoters. b) CIITA is 
mutated in BLS complementation group A. In the absence of CIITA, MHCII and related promoters are occupied by 
the enhanceosome but are not transcribed. c) In BLS complementation groups B, C and D one of the subunits of the 
RFX complex is mutated. In the absence of an intact RFX complex, the enhanceosome can not assemble, CIITA is 
not recruited, and MHCII and related promoters remain silent. 
 
The X box is bound by the trimeric factor RFX, which is composed of RFX5, RFXANK and 
RFXAP. The X2 box is recognized by X2BP [60,61]. Finally, the trimeric complex NF-Y, 
composed of NF-YA, NF-YB and NF-YC, binds to the Y box [62]. Several proteins have been 
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described to bind to the W box, but none has been definitely demonstrated to be the functionally 
relevant W box binding protein. All of the factors binding to the cis-regulatory elements are 
required for MHCII gene expression. However, they are ubiquitously expressed and fail to 
account for either constitutive or IFN-γ inducible MHCII gene expression. Instead, they bind 
cooperatively to the promoter to form a landing pad for an additional factor that plays an essential 
regulatory role [63]. This factor is the class II transactivator CIITA [35]. The latter ultimately 
determines the cell type specificity, inducibility and expression level of MHCII genes. CIITA is 
now widely accepted as being the master regulator of MHCII expression [9,64]. 
 
The RFX complex 
The RFX (regulatory factor X) complex is composed of three subunits RFXANK, RFX5 and 
RFXAP. These factors are defective in BLS complementation groups B, C and D, respectively 
(Fig.6C). The three subunits of the RFX complex are unrelated and share no sequence homology. 
The gene encoding the 75 kD RFX5 subunit was identified by means of a genetic 
complementation approach using a cell line derived from a group C patient [36]. RFX5 was the 
fifth member of the RFX family of DNA binding proteins to be identified [65]. All members of 
this family share a characteristic DNA binding domain (DBD) referred to as the RFX motif 
[65,66]. The three dimensional structure of the RFX motif of one family member (RFX1) has 
been solved and was found to belong to the winged helix subfamily of helix-turn-helix proteins 
[67]. The DBD of RFX5 lies near its N-terminus [68] (Fig.7C). Outside of the DBD, RFX5 
contains no obvious functional motifs. There is a centrally placed proline rich region, of which 
the function remains unknown. 
A biochemical approach was used to isolate the gene encoding the 36 kD RFXAP (RFX 
associated protein) subunit. This approach relied on affinity purification of the RFX complex and 
sequencing of peptides derived from its 36 kD subunit [37]. RFXAP contains an acidic domain, a 
glutamine rich segment and a basic region resembling a bipartite nuclear localization signal 
(NLS) [69,70] (Fig.7D). 
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Figure 7. The domain structure and function of CIITA, RFXANK, RFX5 and RFXAP. a) The 1130 amino acid 
CIITA protein contains an N-terminal acidic domain (DE), an adjacent proline/serine/threonine rich (PST) region, a 
central GTP binding domain and a series of leucine rich repeats (LRR) at the C-terminus. At least three nuclear 
localization signals (NLS 1 to 3) are found in the protein. The N-terminus functions as a transcription activation 
domain and can interact with the indicated general transcription factors and coactivators. The central and C-terminal 
domains are required for recruitment of CIITA to the MHCII enhanceosome and function as a dominant negative 
mutant in the absence of the N-terminal activation domain. Domains believed to be involved in self-association of 
CIITA are indicated. b) The hallmark of the 269 amino acid RFXANK protein is a C-terminal ankyrin repeat 
domain. This domain is sufficient for complementation of cell lines from BLS complementation group B. The N-
terminal part of the protein contains an acidic (DE) domain. c) The 616 amino acid RFX5 protein is the only subunit 
of the RFX complex containing a DNA binding domain (DBD). This DBD lies in an N-terminal region that is 
sufficient for assembly with RFXANK and RFXAP. For complementation of RFX5 defective cell lines, a central 
region containing a proline rich domain (P) is required in addition to the DBD. d) The C-terminus of RFXAP is 
sufficient for complementation of BLS cells lines in group D. Expression of HLA-DR only requires a short segment 
spanning the glutamine rich region (Q). Expression of HLA-DP and HLA-DQ required a larger C-terminal region. 
The acidic region (DE) and NLS-like sequence are not essential for the function of the protein. 
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RFXANK, the gene encoding the smallest 33 kD subunit of RFX was isolated by a biochemical 
approach similar to that used to isolate the RFXAP gene [38]. The gene was named RFXANK 
because it encodes a factor that contains a protein-protein interaction domain consisting of 
ankyrin repeats (Fig.7B). The same gene was isolated independently by another laboratory [39]. 
They called the encoded factor RFXB to indicate that this factor is mutated in BLS 
complementation group B. The N-terminal region of RFXANK is rich in acidic amino acids 
[39,69].  
RFX5, RFXAP and RFXANK assemble to form the RFX complex that binds to the X box of 
MHCII promoters. The complex pre-assembles in solution before binding to its target site. The 
RFX complex can be faithfully reconstituted with the three recombinant proteins, indicating that 
the complex does not contain additional subunits [68-71]. However, the stoichiometry of the 
three subunits in the RFX complex remains to be determined. The absence of any one of the three 
subunits destroys the RFX complex and eliminates its ability to bind to DNA. This is illustrated 
by cell lines from BLS complementation groups B, C and D, which all lack RFX binding activity 
[28,72,73]. Experiments with recombinant RFX proteins have also shown that the individual 
subunits or combinations of two of the subunits are not capable of binding specifically to DNA in 
band shift assays [68-70]. RFX5 is the only RFX subunit containing a well defined DNA binding 
domain, although DNA-protein crosslink experiments have shown that all three subunits contact 
the DNA at the X box [74].  
Specific domains that are necessary for complex formation and DNA binding activity have 
been identified in each of the RFX subunits (Fig.7B-D). In RFX5, the N-terminus (amino acids 
39 to 194) comprising the DBD is sufficient for interaction with RFXAP, RFXANK and X box 
DNA [68,69]. In RFXAP, the 49 C terminal amino acids spanning the highly conserved 
glutamine rich region are sufficient for complex formation and binding to the X box [69,70]. 
Finally, the ankyrin repeat region of RFXANK (amino acids 84 to 269) meets all the 
requirements needed to form an efficient DNA bound complex with RFXAP and RFX5 [69] [our 
unpublished data]. The minimal domain of RFXANK allowing RFX complex formation and 
DNA binding is sufficient to restore MHCII expression in cell lines from RFXANK deficient 
BLS cells [69]. In the case of RFXAP, the minimal 49 amino acid C-terminal region is sufficient 
to restore HLA-DR expression in BLS cells lacking RFXAP [70]. However, a longer segment of 
RFXAP is required to restore expression of HLA-DQ and HLA-DP [70]. The domain of RFX5 
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mediating complex formation and DNA binding (amino acids 39 to 194), is not sufficient for 
complementation of RFX5 deficient cells [68]. An additional domain located between amino 
acids 410 to 515 is required [68]. This region has been shown to mediate cooperative DNA 
binding between RFX and NF-Y [68].  
Outside of the essential domains defined above, several features within RFX appear to be 
dispensable. An acidic region and a putative nuclear localization signal present in RFXAP can be 
removed or mutated without affecting the ability of the protein to restore MHCII expression in 
cells from group D [69,70]. The N-terminal acidic region of RFXANK is not essential because it 
can be removed without eliminating the ability to complement cells from group B [69] [our 
unpublished data]. 
 
The MHCII enhanceosome 
The trimeric RFX complex binds with relatively low affinity to the X box of MHCII 
promoters. However, this binding is greatly stabilized by synergistic interactions with two other 
factors binding to MHCII promoters, namely with the trimeric NF-Y complex [68,71,75] and the 
dimeric protein X2BP [61,76,77]. X2BP has recently been proposed to contain CREB [78]. The 
combination of these cooperative interactions results in stable occupation of MHCII promoters. 
The quaternary complex composed of RFX, X2BP (CREB), NF-Y and MHCII promoter DNA 
is extremely stable with a half-life greatly exceeding that of any of the possible secondary or 
ternary complexes [77]. RFX plays a crucial role in promoting this cooperativity. This important 
role of the RFX complex is strongly emphasized by the analysis of promoter occupation in RFX 
deficient BLS cells (complementation groups B, C and D). MHCII promoters in these cell lines 
are unoccupied and lack the DNaseI hypersensitive sites typically observed in RFX positive cells 
[79-81]. 
The stable higher order nucleoprotein complex that assembles at MHCII promoters has been 
coined the "MHCII enhanceosome" [63]. The enhanceosome can be isolated from cell extracts by 
promoter pull down assays, and has been shown to contain all of the known subunits of RFX, 
X2BP (CREB) and NF-Y [63]. It may also contain additional components but these remain to be 
characterized.  
Formation of the enhanceosome requires the presence and proper arrangement of all cis-
regulatory elements, that is to say the W, X, X2 and Y boxes. The spacing between the X and Y 
 37 
elements is highly conserved at approximately two helical turns [82-84]. Correct stereoalignment 
is essential for promoter activation, probably because the X and Y box binding factors need to be 
assembled on the same side of the DNA helix. It was also observed that the spacing between the 
W and X boxes is critical for promoter activation [83,84] [A.Muhlethaler-Mottet, unpublished 
results]. 
In addition to the crucial role of the MHCII enhanceosome in enhancing the stability and 
specificity of promoter occupation, it constitutes a platform onto which the transcriptional 
coactivator CIITA is recruited. CIITA has been directly implicated as a key protein mediating 
transcriptional activation of MHCII genes (see below). However, it has been recognized recently 
that the enhanceosome also contributes directly to the process of transcription activation 
independently of CIITA [85]. The relative contributions of the enhanceosome and CIITA to 
transcription activation depends on the MHCII promoter [85]. For instance, the enhanceosome 
has a dominant role in histone acetylation and recruitment of general transcription factors (GTF) 
at the DMB promoter. At the DRA promoter on the other hand the dominant role in these 
processes is played by CIITA. Promoters such as DPB depend equally on both the enhanceosome 
and CIITA. The example of the DMB promoter demonstrates that the enhanceosome is not 
merely a landing pad for CIITA, but can actually support CIITA independent events contributing 
directly to transcription initiation. 
B cells display constitutively occupied MHCII promoters, even in the absence of CIITA (cells 
in group A) [80,81]. However, CIITA is clearly required for promoter occupancy in IFN-γ 
induced or CIITA transfected fibroblasts [86-88]. It is not clear how CIITA induces promoter 
occupation in these cells. One possibility is that binding of CIITA favors assembly and/or 
stability of the enhanceosome by interacting with many of its individual components (see below). 
Alternatively, CIITA may facilitate in vivo occupation indirectly by changing accessibility of the 
promoter DNA. 
 
The master regulator CIITA 
The enhanceosome is essential but not sufficient for appropriate MHCII gene expression. This 
is demonstrated by the study of B cell lines from BLS patients in complementation group A. 
Enhanceosome assembly, promoter occupation and the presence of DNase hypersensitive sites 
are all normal at MHCII promoters in these cells (Fig.6B). Yet, the MHCII genes are not 
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transcribed. The defect in this complementation group lies in the MHC2TA gene encoding the 
regulatory factor CIITA [35]. MHC2TA was isolated by the same approach employed for 
isolation of the RFX5 gene, namely by complementation cloning using the in vitro generated cell 
line RJ2.2.5 (complementation group A) [35].  
CIITA expression is a nearly absolute prerequisite for both the constitutive or inducible 
expression of MHCII genes [35,42,89-94].The expression profile of CIITA is the major 
determinant dictating the tightly controlled pattern of MHCII expression [9,64]. The following 
findings emphasize this key regulatory function of CIITA. 1) A quantitative correlation between 
MHC2TA and MHCII expression levels has been revealed by the analysis of a large number of 
human and mouse tissues and cell lines [95]. In addition, an experimental setup using a 
tetracycline inducible system has shown that the level of MHC2TA expression directly 
determines the level of MHCII expression [95]. 2) Most cell types do not express MHC2TA and 
are thus MHCII negative. Transfection of these cells with a CIITA expression plasmid is 
generally sufficient to render them MHCII positive [89,90,96,97]. 3) IFN-γ induces expression of 
the MHC2TA gene, and this mediates activation of MHCII genes [89,96]. 4) Induction of MHCII 
expression upon activation of human T cells is mediated by upregulation of MHC2TA expression 
[98] [our unpublished data]. 5) B cells loose MHCII expression during their differentiation into 
plasmocytes because the MHC2TA gene is repressed [90,99]. Exogenous expression of CIITA is 
sufficient to re-establish MHCII expression in plasmocytes [90,99]. 6) Silencing of MHCII 
expression in trophoblast cells is caused by inhibition of MHC2TA expression [94,100]. 7) 
Cytokines modulating IFN-γ induced MHCII expression, such as TGF-β, IL-1, IL-4 and IL-10, 
do so by modulating MHC2TA expression [101-105]. 8) Pathogens such as cytomegalovirus, 
varicella-zoster virus, Mycobacterium bovis and Chlamydia can downregulate MHCII expression 
by interfering with transcription of the MHC2TA gene [106-109]. In summary, CIITA exerts a 
strict qualitative and quantitative control over MHCII expression and thus deserves the title of the 
master regulator of MHCII expression [9,64]. 
The control of CIITA over MHCII expression is achieved mainly via the level of transcription 
of the MHC2TA gene. However, a few examples of other levels of control are known. The 
inhibitory effect of IFN-β and TNF-α on IFN-γ induced MHCII expression is exerted 
downstream of MHC2TA transcription [110-112]. The transactivating capacity of CIITA can be 
modulated by posttranslational modifications. protein kinase A (PKA) can inactivate CIITA by 
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phosphorylating it at serine residues 834 and 1050 [113]. Phosphorylation of CIITA by PKA is 
thought to be involved in the inhibition of MHCII expression by prostaglandin E (PGE), since 
PKA is a downstream effector in the PGE/cAMP cascade.  
A few examples of CIITA independent MHCII expression have been reported. Isotype 
specific MHCII expression has been observed in certain mutant human cell lines devoid of 
functional CIITA [114]. MHCII expression has also been detected in certain tissues of CIITA-/- 
mice, although the levels are significantly lower than in control animals [42,44]. For the moment, 
these cases of CIITA independent expression remain unresolved exceptions. 
 
Regulation of MHC2TA expression 
The MHC2TA gene is controlled by multiple promoters 
The MHC2TA gene resides in a locus known as AIR-1 on chromosome 16 (16p13) [115]. 
Mhc2ta, the homologous mouse gene, is localized in a syntenic region on mouse chromosome 16. 
The genomic organization of the entire mouse gene has been determined. It consists of 19 exons 
spanning 42 kb of DNA [our unpublished data].  
Expression of MHC2TA is controlled by four different promoters (pI to pIV) [116] (Fig.8). 
Three of these promoters are highly conserved between the human and mouse genes (pI, pIII and 
pIV). pII has only been found in the human gene. It displays only a very low transcriptional 
activity and its significance is not known. pII will thus not be discussed further. The different 
promoters do not share any sequence homology and are not co-regulated. They span a large (> 12 
kb) genomic region. Each promoter precedes a distinct first exon that is spliced alternatively to a 
shared second exon. This leads to the production of three types of transcript (type I, type III and 
type IV), each possessing a different 5' end [116] (Fig.8).  
The shared second exon contains an AUG translation initiation codon that can be used in all 
three types of transcript to give rise to a 1106 amino acid protein. However, the first exons of the 
type I and type III transcripts each contain an additional in-frame translation initiation codon. 
Usage of these alternative start codons leads to the synthesis of protein isoforms of 1207 and 
1130 amino acids, respectively. The three CIITA isoforms have apparent molecular weights of 
132 kD, 124 kD and 121 kD (Fig.8). All three protein variants exist in vivo. The first CIITA 
cDNA clone to be isolated corresponded to a CIITA type III mRNA. Therefore, nucleotide and 
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amino acid numbering are generally given with respect to the transcription initiation site of type 
III mRNA and the translational initiation codon of the 1130 kD isoform. 
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Figure 8. Expression of the MHC2TA gene is controlled by four different promoters (pI to pIV). pI is active in 
dendritic cells and in IFN-γ activated monocytes and macrophages. pII is only found in humans and its significance 
is unknown. pIII is used in B cells, in activated human T cells and in some types of dendritic cells. pIV is responsive 
to IFN-γ and is constitutively expressed in cTECs. The three types of mRNAs (types I, III and IV) initiated at pI, pIII 
and pIV encode three different protein isoforms (121, 124 and 132 kD). These proteins differ only at their N-terminal 
end. Gray bars represent exons. white bars represent mRNAs and black bars represent proteins encoded by these 
mRNAs. The boundary between the alternative first exons and the shared downstream exons is indicated by a 
vertical line. The positions of translation initiation codons are indicated.  
 
The N-terminal extensions encoded by the unique first exons of CIITA type I and type III 
mRNAs may confer specific properties on the corresponding 132 kD and 124 kD CIITA 
isoforms. It has been suggested that the 132 kD isoform of CIITA, which is mainly expressed in 
DCs, has an enhanced capacity to activate MHCII transcription compared to the smaller two 
isoforms [117] [Luc Otten, unpublished results]. In addition, this isoform seems to have an 
extremely short half-life [our unpublished observations]. It is likely that these features are due to 
an intrinsic property of the N-terminus unique to this CIITA isoform. A recent study has 
proposed that the N-terminal extension of the 132 kD isoform displays homology to caspase 
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recruitment domains (CARD) [117], which are found in components of the apoptosis and NF-κB 
signaling pathways [118,119]. The significance of this is not clear because CIITA is not known 
to be involved in either of these pathways.  
Cell type specific and modulated expression of the MHC2TA gene is controlled by the 
differential activities of the three promoters. It is thus the sophisticated transcriptional control of 
the MHC2TA gene that dictates the cell type specific and inducible expression of MHCII genes.  
 
pI and expression of MHC2TA in DC 
MHC2TA pI is highly specific for DCs. CIITA type I transcripts always represent a 
preponderant fraction in various DC preparations including ex vivo mouse DCs, mouse bone 
marrow-derived DCs, long-term mouse DC cultures and human monocyte-derived DCs 
[116,120-122] [our unpublished data]. However, CIITA type III transcripts are also found in 
significant amounts in certain DC preparations [121]. Moreover, DC specificity of pI is not as 
absolute as first thought. pI can for instance also be induced by IFN-γ in microglia and peritoneal 
macrophages [120,122].  
A recent report from our laboratory has characterized in detail the activity of pI (and pIII) 
during the course of maturation of human monocyte-derived DCs [121]. In response to a variety 
of stimuli, such as infection by bacteria or viruses, immature DCs are induced to undergo 
profound changes in their morphology and function. Changes in the expression of MHCII 
represent a key aspect of this maturation process. The number of MHCII molecules expressed at 
the cell surface is increased as a result of changes in the intracellular localization and stability of 
preexisting MHCII protein. In contrast, de novo synthesis of MHCII molecules is shut down. 
This reduction in MHCII synthesis during DC maturation is a consequence of rapid silencing of 
the MHC2TA gene. The arrest in CIITA expression is the result of a transcriptional inactivation 
of the MHC2TA gene. This is mediated by a global repression mechanism implicating histone 
deacetylation over a large domain spanning the entire MHC2TA regulatory region, including the 
two promoters (pI and pIII) that are active in DCs. 
 
pIII and expression of MHC2TA in B cells 
MHC2TA pIII is used primarily in B cells [116,123], activated human T cells [98] [our 
unpublished observations] and to a lesser extent in some DC subsets [116,121]. Aberrant CIITA 
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expression in melanoma cells was also reported to be initiated at pIII [124,125]. A 320 bp 
promoter proximal regulatory region is sufficient for B cell specific activity [116,123]. This 
region contains five sequence elements that can be shown to be occupied in vivo in B cells in 
genomic footprinting experiments [126] (Fig.9B). At least two of these elements are critical for 
proper activity, namely a TEF-2 like element and a binding site for a novel transcription factor 
[126]. 
A 5' flanking sequence situated approximately five kb upstream of the transcription initiation 
site of pIII of the human MHC2TA gene has been reported to confer IFN-γ responsiveness [103]. 
The functional relevance of this sequence is supported by the presence of a DNaseI 
hypersensitive site at this position in vivo [127]. The putative regulatory region acts as a STAT-1 
dependent and IRF-1 independent enhancer [127]. In contrast to these findings in human cells, 
pIII does not seem to be inducible by IFN-γ in primary rat astrocytes [112] and in mouse 
macrophages [122]. There may thus be a species specific difference in the IFN-γ responsiveness 
of pIII. 
Expression of the MHC2TA gene is actively silenced during terminal differentiation of B cells 
into plasmocytes [90,99]. The sequence elements of pIII that are occupied in normal B cells are 
completely bare in plasmocytes [90,126]. The human positive regulatory domain I binding factor-
1 (PRDI-BF1) [128] and its mouse homologue B lymphocyte-induced maturation protein-1 
(Blimp-1) [129] have been proposed to play a crucial role in the repression of pIII in plasmocytes 
[130,131]. PRDI-BF1/Blimp-1 is upregulated when B cells differentiate into plasmocytes [132]. 
It has also been shown to drive, at least partially, the final differentiation of B cells into 
plasmocytes if expressed ectopically in BCL1 lymphoma cells [132]. PRDI-BF1/Blimp-1 can 
bind specifically to a sequence in the promoter proximal region of pIII [130,131]. However, no 
occupation of this site is seen in in vivo footprint experiments performed with plasmocytes [126]. 
The mechanism, by which PRDI-BF1/Blimp-1 silences the MHC2TA gene, is thus not well 
understood.  
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Figure 9. The promoter proximal regions of CIITA pI, pIII and pIV contain several cis-regulatory elements. 
a) The regulation of pI is not well understood. The depicted elements represent only potential consensus binding 
sites. The arrowheads represent protections and enhancements observed in in vivo footprint experiments at the sense 
(downwards) and antisense (upwards) strands in human dendritic cells. b) pIII contains five cis-regulatory elements 
defined by in vivo footprint experiments (arrowheads). They are called site A, site B, ARE-2, ARE-1 and site C. In 
vitro binding studies have revealed that ARE-1 may be bound by AML2 in B and T cells, ARE-2 by a member of the 
CREB/ATF protein family in B and T cells, site A by NF-1 in B cells and site C by PRDI-BF1 in plasmocytes. c) 
The regulation of IFN-γ induced pIV expression is well understood. Binding of IFN-γ to its receptor induces JAK-1 
and JAK-2 activation and thus STAT-1 phosphorylation, dimerization and translocation to the nucleus. STAT-1 
binds cooperatively with USF-1 to a composite GAS/E box motif. STAT-1 also activates expression of IRF-1, which 
then binds to its cognate site in pIV. The arrowheads depict protections and enhancement observed in in vivo 
footprint experiments. The mechanism mediating expression of pIV in cTECs is not known. 
 
pIV and IFN-γ induced MHC2TA expression 
MHC2TA pIV is induced by IFN-γ in most cell types, including cells of the 
monocyte/macrophage lineage, endothelial cells, fibroblasts, astrocytes and cTECs 
[103,105,110,116,127,133]. A 300 bp promoter proximal region is sufficient for the IFN-γ 
response [116,127,133]. This region contains a GAS element, an E box and an IRF-1 binding site 
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(Fig.9C), all three of which are required for induction in most cell types [103,110,116,133,134]. 
The former two are bound cooperatively by STAT-1 and upstream regulatory factor-1 (USF-1) 
[103,110,133]. STAT-1 is activated and translocated to the nucleus by the classical IFN-γ signal 
transduction pathway. USF-1 is a constitutively expressed member of the basic helix-loop-
helix/leucine zipper family. In rat astrocytes, STAT-1 is dispensable for IFN-γ induced activation 
of pIV [112]. This may represent a species or cell type specific exception to the general 
requirement for STAT-1 in IFN-γ induced pIV activity. The IRF-1 binding site of pIV is 
occupied by IRF-1. IRF-1 synthesis itself is induced by IFN-γ. Thus, the dependence of CIITA on 
IRF-1 explains the delayed kinetics of CIITA induction by IFN-γ. [89]. One group has proposed 
that IRF-1 and IRF-2 bind cooperatively to pIV [135], and found a reduction of CIITA 
expression in IRF-2 knockout mice [136]. IRF-2 may thus also be involved in activation of pIV. 
IFN-γ activated expression of CIITA can be suppressed by a number of different stimuli. TGF-
β markedly attenuates IFN-γ induced CIITA expression. The inhibitory mechanism involves 
suppression at the level of MHC2TA transcription [101,102,104]. Surprisingly, TGF-β does not 
affect IFN-γ induced phosphorylation of JAK-1, JAK-2 and STAT-1. Nor does it interfere with 
binding of STAT-1, USF-1 or IRF-1 to pIV of the MHC2TA gene [137,138]. Moreover, TGF-β 
even inhibits basal non-induced expression levels of pIV [103,139]. Finally ,activity of the 
putative IFN-γ response element situated upstream of pIII is also inhibited by TGF-β [127]. A 
recent report has implicated Smad-3 in the inhibitory effect of TGF-β on CIITA expression [138]. 
IL-1, IL-4 and IL-10 have also been shown to exert an inhibitory effect similar to TGF-β on 
CIITA transcription in human astrocytes (IL-1) [105] and in mouse microglia cells (IL-4, IL-10) 
[104]. The role of IL-4 mediated CIITA inhibition seems to be cell type dependent.  
IFN-γ induced gene activation is generally a transient event. Suppressor of cytokine signaling-
1 (SOCS-1) has been shown to be induced by IFN-γ and this protein negatively regulates the 
IFN-γ signal transduction pathway by binding to JAK-2 and inhibiting its kinase activity 
[140,141]. SOCS-1 can thus also suppress IFN-γ activated expression of pIV of the MHC2TA 
gene [134]. 
Trophoblasts lack MHCII and CIITA expression in order to evade maternal immune 
recognition. They do not respond to IFN-γ, although MHCII can be induced by ectopic 
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expression of CIITA in these cells [94,100]. Recently, two laboratories have reported that 
suppression of CIITA expression in trophoblasts is due to methylation of pIV [142,143]. 
 
Lessons from pIV knockout mice 
Mhc2ta pIV knockout mice have been generated in our laboratory [122]. These mice allowed 
us to define precisely the cell type specificity of pIV in vivo. pIV -/- mice exhibit selective 
abrogation of IFN-γ induced MHCII expression on a wide variety of non-hematopoietic cells, 
including endothelia, epithelia, astrocytes and fibroblasts. The cTECs of these mice are also 
MHCII negative. In contrast, constitutive and inducible MHCII expression is unaffected on 
professional APCs including B cells, DCs and IFN-γ activated cells of the monocyte/macrophage 
lineage.  
The phenotype of the pIV -/- mice demonstrates that professional APCs do no depend on pIV 
for IFN-γ inducible expression of CIITA. Ex vivo macrophages from control mice use both, pI 
and pIV in response to IFN-γ. Macrophages from pIV deficient animals express similar amounts 
of total CIITA mRNA in response to IFN-γ but transcripts are derived exclusively from pI. It 
remains unknown, how IFN-γ activates pI. No IFN-γ responsive sequences have been identified 
in the vicinity of pI. It is thus possible that IFN-γ may affect pI indirectly as a consequence of 
macrophage activation. The answer to this question awaits further dissection of the regulatory 
mechanism controlling pI.  
The finding that constitutive MHCII expression on cTECs is abolished was completely 
unexpected. The loss of MHCII molecules on cTECs in the pIV knockout mice results in the 
abrogation of positive selection of CD4+ T cells in the thymus. CD4+ T cell counts in these mice 
are strongly reduced in the thymus and in the periphery. pIV is thus essential for positive 
selection of CD4+ T cells.  
Isolated cTECs loose MHCII expression if they are not maintained in three-dimensional re-
aggregate thymus organ cultures [144,145]. This indicates that a stimulus must be required to 
maintain constitutive MHCII expression on cTECs. This stimulus could be provided either by 
cell-cell interactions between the cTECs or by a short acting soluble factor produced by the 
cTECs. The precise nature of the signal required for MHCII expression in cTECs as well as its 
mode of action is still unknown. The phenotype of the pIV-/- mice indicates that this signal 
functions by activating pIV of the MHC2TA gene. However, it must achieve this via a 
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mechanism that is independent of the IFN-γ signaling pathway, because knockout mice lacking 
key components of this pathway, such as the IFN-γ receptor, STAT-1 and IRF-1, have normal 
MHCII expression on cTEC and normal positive selection of CD4+ T cells. 
The Mhc2ta pIV knockout mice have provided definitive evidence that differential CIITA 
promoter usage does indeed play an important physiological role. They have also allowed us to 
draw a more accurate picture of the differential promoter usage. Cells of myeloid origin (DCs, 
monocytes/macrophages) use mainly pI for constitutive or IFN-γ induced CIITA expression. 
Constitutive CIITA expression in cells of lymphoid origin (B cells, T cells) is driven by pIII. 
Finally, pIV is indispensable for IFN-γ activated expression in non-hematopoietic cells and for 
expression in cTECs.  
 
Structure and function of CIITA 
Structure of CIITA 
Given the key role of CIITA as the master regulator of MHCII expression, a considerable 
amount of effort has been devoted to the elucidation of its structure and mode of action. Analysis 
of the primary sequence of CIITA has revealed four major features of interest, namely an N-
terminal acidic domain, an adjacent proline/serine/threonine rich (PST) region, a central GTP 
binding domain and a series of leucine rich repeats (LRR) at the C-terminus [9,64] (Fig.7A). 
Several other proteins have been found to share a similar domain structure. In particular, the 
nucleotide binding domain and the leucine rich repeats are conserved in a number of proteins 
[64]. Intriguingly, these proteins have functions very distinct from that of CIITA. They include 
for instance Nod-1, which induces activation of caspase-9 and NF-κB, and certain plant 
resistance proteins [119,146]. The similarity in the domain structure between CIITA and these 
unrelated proteins may indicate a yet unknown analogy in their mode of action. 
 
Recruitment of CIITA to the MHCII enhanceosome 
In vivo association of CIITA with MHCII and related promoters was recently demonstrated by 
chromatin immunoprecipitation experiments [63,147]. Moreover, DNA dependent co-
immunoprecipitation assays and pull-down experiments using immobilized promoter templates 
have demonstrated a direct physical interaction between CIITA and the MHCII enhanceosome 
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[63]. This interaction requires the integrity of the enhanceosome and depends on multiple, 
synergistic protein-protein interactions with the multiple factors constituting the enhanceosome.  
CIITA has been demonstrated to interact with several components of the MHCII 
enhanceosome. An interaction with RFX5 was first revealed in a yeast-two-hybrid system [148]. 
In vitro interactions were subsequently also demonstrated with RFX5, RFXANK, NF-YB, NF-
YC and CREB [69,84,149]. The regions of CIITA that are required for recruiting CIITA to the 
enhanceosome [63,149] and for co-immunoprecipitation with these proteins [84] have been 
partially mapped. 
 
Activation of transcription by CIITA 
CIITA activates transcription of MHCII genes when recruited to the enhanceosome. The 
regions of the protein that are essential for this transactivation have been mapped to the N-
terminal acidic and PST domains [150-152]. These domains are believed to constitute 
transcription activation domains and they resemble the activation domains found in other 
transcription factors. When fused to a GAL4 DNA binding domain, the N-terminus of CIITA can 
activate transcription of a reporter gene [150]. Moreover, the transcription activation domains of 
VP16 and HSV1α transducing factor can substitute for the N-terminus of CIITA [150,151]. This 
substitution is only partial, indicating that the N-terminus of CIITA may also support additional 
functions.  
Deletion of the acidic and (or) PST domains results in dominant negative mutants that repress 
the activity of wild type CIITA in B cells and fibroblasts [152-156]. In vitro promoter pull down 
experiments have shown that these dominant negative mutants of CIITA are recruited more 
efficiently to MHCII promoters than wild type CIITA [63]. This suggests that their dominant 
negative phenotype is due at least in part to an increased affinity for the enhanceosome. 
Various general transcription factors or coactivators can interact with the N-terminus of CIITA 
(Fig.10). The TAFII32 and TAFII70 subunits of the TFIID complex, TFIIB, TFIIH, pTEFb, CBP 
and pCAF have been shown to be able to interact with this region [154,157-160]. This suggests 
that the N-terminus of CIITA acts as a transcriptional activation domain recruiting factors 
involved in transcription initiation (TFIID, TFIIB), promoter clearance and transcription 
elongation (TFIIH, pTEFb), or chromatin remodeling (CBP, pCAF). The interactions of CIITA 
with CBP and pCAF have been addressed in greater detail. First, CBP and pCAF can both 
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increase, synergistically with CIITA, the expression of a HLA-DRA reporter gene [158,161,162]. 
Surprisingly, this cooperativity has been shown to be independent of the histone acetyltransferase 
(HAT) activity of CBP and pCAF [162]. Second, the synergy between CIITA and CBP is 
inhibited by a dominant negative variant of CBP [158]. Finally, when overexpressed, CIITA can 
sequester CBP and thus downregulate other CBP dependent genes [158] (see below)[163].  
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Figure 10. CIITA is a non-DNA binding transcriptional coactivator that functions via multiple protein-protein 
interactions. Interactions with several enhanceosome components tether CIITA to MHCII and related promoters. 
Once tethered to the promoter, CIITA is believed to activate transcription by recruiting other factors including TFIIB, 
TFIID, TFIIH, pTEFb, CBP and pCAF. These factors are involved in transcription initiation (TFIIB, TFIID), promoter 
clearance and transcription elongation (TFIIH, pTEFb) and chromatin remodeling (CBP, pCAF). Protein-protein 
interactions are indicated by double headed arrows. 
 
Acetylation of lysines in the N-terminal tails of histones H3 and H4 is generally associated 
with increased transcriptional activity of eukaryotic genes [164-166]. In MHCII and related 
genes, increased acetylation of histones H3 and H4 correlates with binding of CIITA to the 
enhanceosome in various cell types [85,147]. The high acetylation status observed in the wild 
type B cell line Raji is strongly reduced in the CIITA deficient cell line RJ2.2.5 [85,147]. In IFN-
γ induced HeLa cells, the kinetics of the increase in H3 and H4 acetylation correlates well with 
the binding of CIITA to the HLA-DRA promoter [147]. Both processes are very dynamic. 
Binding of CIITA and acetylation start to increase within a few hours after induction by IFN-γ, 
are maximal after 24 hours and then decrease. Acetylation of the HLA-DRA promoter is 
pronounced at the promoter proximal region [85,147] but is also seen as far as 15 kb upstream of 
the transcription initiation site [K.Masternak, unpublished results] Multiple HAT activities may 
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be involved in histone acetylation at MHCII promoters. These include the CBP and pCAF co-
activators that can bind to CIITA. It has also been proposed that CIITA itself contains an intrinsic 
acetyl transferase activity [167].  
 
The GTP binding domain and the leucine rich repeat region 
CIITA is the first transcription factor known to have a GTP binding domain. This GTP 
binding domain (amino acids 421 to 561) is composed of a Walker A motif (also called P loop) 
involved in phosphate binding, a magnesium binding site and a guanine coordination site. This 
tripartite motif is essential for GTP binding and CIITA function [152,168]. Mutants of the GTP 
binding domain fail to translocate to the nucleus (see below). Mice bearing a deletion spanning 
the GTP binding domain of the Mhc2ta gene display a phenotype similar to that of other CIITA 
knockout mice [45].  
LRR domains are known to mediate protein-protein interactions and are found in many 
different classes of proteins. The LRRs found at the C terminus of CIITA (amino acids 988 to 
1097) are essential for its function [149,169]. Partial deletion of these LRRs generates a CIITA 
mutant displaying a dominant negative phenotype [169]. 
 
Dimerization of CIITA 
Several laboratories have reported that CIITA can bind to itself via intra- or intermolecular 
contacts [170-172]. However, there is no uniform consensus on the precise regions involved in 
this self-association. The central region encompassing the GTP binding site may contact the 
acidic and PST region [170,172] or may instead bind to the C-terminus [171,172]. LXXLL 
motifs residing in the GTP binding domain may play a crucial role for self-association [172]. In 
vitro translated CIITA does not dimerize, indicating that additional factors or modifications may 
be involved [170-172]. Finally, the precise role of self-association of CIITA is not certain. It may 
play a role in subcellular localization of CIITA [170]. It should be mentioned here that many of 
the results described above have been obtained under conditions of overexpression of CIITA and 
should therefore be interpreted with caution. 
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Nuclear localization of CIITA 
Depending on the cell type and the method of detection, CIITA is either found in both the 
nucleus and cytoplasm or found predominantly in the nucleus [149,160,168,170,173,174]. As 
mentioned above for dimerization, nuclear localization studies have been done mainly with 
overexpressed CIITA. Three potential NLS's have been identified in CIITA (Fig.7A). NLS1 
(amino acids 141 to 159) resembles a bipartite NLS [160]. Nuclear localization mediated by 
NLS1 is affected positively by CBP and pCAF, but this is independent of their HAT activity 
[160,162]. NLS2 has been localized between amino acids 405 and 414 [174]. It displays 
similarity to the classical SV40 NLS. Deletion of NLS2 results in cytoplasmic localization and 
the loss of transactivation by CIITA [174]. Finally, NLS3 was identified thanks to a BLS patient 
expressing a CIITA mutant that lacks an exon spanning amino acids 940 to 963 [173]. This exon 
contains a RFLKK motif that functions as a NLS. The loss of this exon abolishes nuclear import 
of CIITA [173]. In addition to the three NLS's, GTP binding and integrity of the LRRs have been 
found to be crucial for proper nuclear import of CIITA [149,168,175]. Finally, nuclear export 
sequences (NES's) have also been found to influence the subcellular distribution of CIITA. Two 
regions in CIITA have been found to be crucial for nuclear export and can bind to the export 
receptor CRM1 [170]. The presence of both NLS's and NES's suggests that CIITA shuttles back 
and forth between the nuclear and cytoplasmic compartments. 
 
The role of CIITA and the enhanceosome in MHCI expression 
In addition to their crucial role in MHCII gene expression, both CIITA and the MHCII 
enhanceosome contribute to the regulation of MHCI genes [63,176-178]. The W, X, X2 and Y 
sequence elements characteristic of MHCII promoters are also present in the promoter proximal 
regions of the MHCI and β2m genes. The X2 element in MHCI promoters corresponds to a 
sequence that was first called site α. The latter was defined as a sequence that has homology to 
the cAMP response element (CRE) and is bound by members of the ATF/CREB family. The Y 
box of MHCI promoters was initially called enhancer B. CIITA and the RFX complex contribute 
to the expression of MHCI genes by interacting with the W-X-X2-Y region of MHCI promoters. 
This has been demonstrated by chromatin immunoprecipitation experiments and by 
transactivation assays [63,176-178]. The contribution of CIITA and RFX to the activation of 
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MHCI promoters explains the finding that BLS patients frequently have reduced levels of MHCI 
expression [11,12].  
Compared to their essential role at MHCII promoters, CIITA and RFX contribute only 
relatively weakly to the expression of MHCI genes. This is evident from the phenotype of BLS 
patients, which exhibit a complete absence of MHCII expression but retain strong, albeit reduced, 
levels of MHCI expression [11,12]. The same is also true for mouse models of the human disease 
[42-45]. CIITA deficient mice do not display significantly reduced MHCI expression. In RFX5 
deficient mice MHCI expression is reduced two to ten fold in certain cell types (B and T 
lymphocytes) [our unpublished data]. The fact that RFX and CIITA are less important for MHCI 
expression is readily explained by the presence of additional key regulatory sequences present in 
the promoters of MHCI and β2m genes. 
 
Additional targets of CIITA 
Although MHCII and related genes are undoubtedly the major target genes of CIITA, it has 
recently also been implicated in other systems. For several genes it has been proposed that CIITA 
functions as a negative regulator. These include the IL-4 gene, the Fas ligand gene and the 
collagen α2 (I) gene [163,179,180]. In all three examples, sequestration of CBP by CIITA has 
been proposed to account for the repression. The same mechanism may also be implicated in 
downregulation of the thymidine kinase and cyclin D1 genes [163]. 
IL-4, a Th2-type cytokine, was found to be aberrantly expressed in Th1 cells derived from 
CIITA knock-out mice [179]. Moreover, ectopic expression of CIITA in Th2 cells from CIITA 
knockout mice was found to suppress the expression of Th2 cytokines [179]. Taken together, 
these results suggested that CIITA can inhibit expression of the IL-4 gene. The negative effect of 
CIITA was proposed to be due to a competition between NF-AT, an essential IL-4 gene 
transcription factor, and CIITA for binding to CBP [181]. Whether repression of IL-4 expression 
by CIITA actually occurs in vivo remains to be demonstrated. In this respect it should be 
mentioned that ectopic expression of CIITA at physiological levels in transgenic mice does not 
affect IL-4 expression in Th2 cells [Luc Otten, unpublished data].  
NF-AT is also an important transcription factor for Fas ligand expression. As for the IL-4 
gene, the activity of NF-AT on the FasL promoter was shown to be repressed by overexpression 
of CIITA [180].  
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The collagen α2(I) gene was recently recognized as a new target for repression by CIITA 
[163]. The mechanism proposed for downregulation of this gene again involves binding of CIITA 
to CBP.  
The promoter of the HIV provirus recently attracted attention as a novel target of 
transcriptional regulation by CIITA. Saiffudin et al. reported that expression of CIITA increases 
LTR promoter activity and HIV replication in fibroblast and T cell lines [182,183]. This was 
speculated to be relevant because CIITA is expressed in activated human T cells and 
macrophages, both of which are primary targets of HIV infection. However, in other studies HIV 
infection and LTR activity were found to be reduced in CIITA positive B and T cell lines 
[184,185]. It is therefore presently not clear exactly how CIITA affects the level of transcription 
from the HIV promoter under physiological conditions.  
The viral transactivator Tat was reported to be able to downregulate MHCII expression in HIV 
infected or Tat transfected fibroblasts and T cell lines [159,184,186]. MHCII protein and mRNA 
levels were reduced in these cells while CIITA expression levels were not affected. Conversely, 
overexpression of CIITA was found to inhibit Tat-mediated transactivation of the HIV-1 LTR 
[184]. Tat and CIITA can both bind to the same surface in cyclin T1, one of the subunits of the 
elongation factor pTEFb. It was therefore proposed that CIITA and Tat compete for binding to 
pTEFb [159,184]. In addition, a mechanism independent of pTEFb has also been implicated in 
inhibition of CIITA activity by Tat [187]. Taken together, these findings suggest that the actions 
of Tat and CIITA may be mutually antagonistic. It is likely that the precise outcome of the 
reciprocal actions of Tat and CIITA will depend on the relative concentrations of the two proteins 
and possibly on the cell type in which they are expressed. It remains to be determined if Tat is 
inhibited by or inhibits CIITA in vivo during the course of infection by HIV. 
 
CIITA as a target of pathogens 
Pathogens have developed a wide variety of strategies to escape immune surveillance by their 
hosts. In order to inhibit the establishment of a protective immune response, several bacteria and 
viruses have acquired the ability to downregulate MHCII expression and thus prevent activation 
of specific CD4+ T cells. They achieve this by interfering with the function or expression of 
CIITA. The intracellular bacterium Chlamydia downregulates CIITA expression by inducing 
degradation of USF-1, an ubiquitous factor that is required for the activation of pIV of the 
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MHC2TA gene [108]. Infection with Mycobacterium bovis bacillus Calmette-Guérin also 
downregulates CIITA expression, but the precise mechanisms that is involved remains unknown 
[107]. Varizella zoster virus inhibits IFN- γ induced transcription of the MHC2TA gene by 
interfering with the IFN-γ signaling pathway. It blocks STAT1α and JAK2 protein expression 
and therefore transcription of the downstream IRF-1 and CIITA genes [109]. Human 
Cytomegalovirus has also developed mechanisms to modulate IFN-γ induced CIITA expression. 
Infection with this virus can direct JAK-1 protein to the proteasome for degradation or affect the 
IFN-γ signaling pathway downstream of STAT phosphorylation and nuclear translocation 
[106,188]. Finally, as mentioned above, the HIV Tat protein can inhibit MHCII expression by 
interfering with the function of CIITA [159,184,186]. Taken together, these findings demonstrate 
that many pathogens have acquired a means to target CIITA in order to escape immune 
recognition and establish persistence. It will be of great interest to further our understanding of 
the strategies used by pathogens to interfere with CIITA and MHCII expression. This will 
contribute to the design of new approaches for fighting these pathogens. 
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2.3 Dendritic cells 
2.3.1 The role of dendritic cells in the immune system 
Host defense relies on a concerted action of both antigen-nonspecific innate immunity and 
antigen-specific adaptive immunity (140, 141). Key features of the innate immune system include 
the ability to rapidly recognize pathogens and/or tissue injury and the ability to signal the 
presence of danger to cells of the adaptive immune system (142). The innate system includes 
phagocytic cells, natural killer (NK) cells, complement and interferons (IFNs). Cells of the innate 
system use a variety of germline-encoded pattern recognition receptors to recognize patterns 
shared between pathogens, for instance bacterial LPS, carbohydrates, and double-stranded viral 
RNA (143-145). Evolutionary pressure has led to the development of adaptive immunity, the key 
features of which are the ability to rearrange genes of the immunoglobulin family, permitting 
creation of a large diversity of antigen-specific clones and immunological memory. Yet this 
highly sophisticated and potent system needs to be instructed and regulated by APCs. DCs are 
unique APCs because they are the only ones that are able to induce primary immune responses, 
thus permitting establishment of immunological memory (98-100). 
DCs represent a heterogeneous cell population, residing in most peripheral tissues, particularly 
at sites of interface with the environment (skin, mucosae) (98). They display a high phagocytic 
capacity. Following tissue damage, DCs process the captured antigens, load them on MHC 
molecules and migrate to the lymphoid organs, where they present the antigenic peptides in the 
context of MHC molecules to T cells, thereby initiating adaptive immune responses (146, 147). 
DCs activate antigen-specific CD4+ T helper cells, which in turn regulate the immune effectors, 
including antigen-specific CD8+ cytotoxic T cells (CTLs) and B cells, as well as non-antigen-
specific macrophages, eosinophils and NK cells. Moreover, DCs educate effector cells to home to 
the site of injury (98). Four stages of DC development have been delineated, including 1) bone 
marrow progenitors; 2) precursor DCs that are patrolling through blood and lymphatics as well as 
lymphoid tissues, and that upon pathogen recognition, release large amounts of cytokines, e.g. 
IFN-α, thereby limiting the spread of infection; 3) tissue-residing immature DCs, which possess 
high endocytic and phagocytic capacity permitting antigen capture; and 4) mature DCs, present 
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within secondary lymphoid organs, that express high levels of costimulatory molecules 
permitting antigen presentation (Fig.11).  
 
 
 
Figure 11. The life cycle of DCs. Circulating precursor DCs enter tissues as immature DCs. They may directly 
encounter pathogens that induce secretion of cytokines (e.g. IFN-α). Immature DCs reside at strategically important 
sites in the periphery to encounter pathogens. After antigen capture, immature DCs migrate to lymphoid organs 
where, after maturation, they display peptide-MHC complexes, which allows selection of rare circulating antigen-
specific lymphocytes. These activated T cells help DCs in terminal maturation, which allows lymphocyte expansion 
and differentiation. Activated T lymphocytes migrate and reach the injured tissues. Helper T cells secrete cytokines, 
which permit activation of macrophages, NK cells and eosinophils. Cytotoxic T cells eventually lyse the infected 
cells. B cells become activated after contact with T cells and DCs and then mature into antibody-producing plasma 
cells. It is believed that, after interaction with lymphocytes, DCs die by apoptosis. 
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2.3.2 Immature dendritic cells 
Immature DCs reside in peripheral tissues at sentinel positions where they sample self and 
non-self antigens. However, they are not able to present the antigens. Immature DCs accumulate 
MHC molecules intracellularly and present only a small fraction at the cell surface (103, 104). 
Three types of antigen uptake are known: macropinocytosis, phagocytosis and clathrin-
mediated endocytosis (101, 102). Different types of antigens are internalized via these different 
routes. The constitutive and cytoskeleton-dependent process of macropinocytosis allows rapid 
and non-specific sampling of large amounts of surrounding fluid and results in the formation of 
large intracellular vacuoles. Phagocytosis is a receptor-mediated process dependent on regulated 
actin assembly. In general, the same receptors mediating phagocytosis of pathogens are also 
engaged in clathrin-dependent endocytosis. The latter allows uptake of macromolecules through 
specialized regions of the plasma membrane, termed coated pits (148). A large number of 
endocytic receptors are expressed on immature DCs, namely C-type lectins (101, 149, 150), 
receptors for the Fc portion of immunoglobulins (FcRs) (151, 152), complement receptors (153), 
receptors for heat shock proteins (154, 155), and scavenger receptors (156).  
 
2.3.3 Dendritic cell activation and maturation 
A signal from pathogens, often referred to as a danger signal (157), induces DCs to enter a 
developmental program, called maturation, which transforms DCs from sentinels into efficient 
APCs and T cell stimulators (98). The danger signal can be a bacterial or viral product as well as 
an inflammatory cytokine. Danger signals are recognized through specific pattern-recognition 
receptors, such as Toll-like receptors, FcRs and cytokine receptors (151, 158).  
With the induction of maturation, DCs undergo massive morphological and functional 
changes. Antigen internalization is downmodulated due to repression of most antigen-receptors 
and to an overall reduction in phagocytosis and macropinocytosis (101). In addition, MHC 
molecules are redistributed from intracellular endocytic compartments to the cell surface (103, 
104). Peptide loading as well as the half-life of MHC molecules is increased (103, 104). Finally, 
the surface expression of T cell costimulatory molecules also rises.  
Concomitant with the modifications of their antigen presentation abilities, maturation induces 
migration of DCs out of peripheral tissues (105). Modifications in the expression of chemokine 
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receptors and adhesion molecules, as well as profound changes of the cytoskeleton organization, 
contribute to the migration of DCs, through the lymph, towards secondary lymphoid organs 
(106). By linking antigen uptake, peptide loading, and cell migration to the encounter of a danger 
signal, DCs restrict antigen presentation to those antigens internalized during maturation, thus 
favoring the stimulation of T cells specific for potentially pathogenic antigens.  
 
2.3.4 Antigen presentation by dendritic cells 
CD8+ and CD4+ T cells express clonally distributed TCRs that recognize antigenic peptides 
associated with MHCI and MHCII molecules, respectively. A strict compartmentalization of 
MHCI and MHCII biogenesis results in the loading of exogenous antigens on MHCII molecules 
in the endocytic pathway, and the selective loading of endogenous antigens on MHCI molecules 
in the ER. This model accounts for the selective killing by MHCI-restricted CD8+ T cells of 
virus-infected cells (expressing endogenous viral antigens), but not of neighboring cells that have 
internalized inactive virus or apoptotic cells. 
Peptides to be loaded onto MHCI molecules are generated by proteasome-mediated 
degradation of newly synthesized ubiquitinylated proteins (Fig.12). The immunoproteasome, 
which is expressed at low levels in immature DCs, becomes the main type of proteasome in 
mature DCs (107-109). The peptides resulting from proteasome mediated degradation are 
transferred to the ER by a specialized peptide transporter, TAP, and loaded onto newly 
synthesized MHCI molecules under the control of several ER resident chaperones (159). MHCI-
peptide complexes are then rapidly transferred through the Golgi apparatus to the plasma 
membrane. MHCI synthesis and half-life are slightly increased during DC maturation (103, 104).  
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Figure 12. MHCI restricted antigen presentation. Pathogen-derived or self-proteins within the cytosol of APCs 
are enzymatically digested into peptides, mainly by the cytosolic protease called proteasome, and are then 
transported by TAP molecules into the ER. In the ER lumen, peptides bind to MHCI molecules, which are 
subsequently transported via the Golgi to the plasma membrane. 
 
The formation of MHCII-peptide complexes in DCs is induced by maturation. This is different 
from the situation in other APCs, where this process is constitutive. In immature DCs, most 
MHCII molecules are retained in late-endosomal and lysosomal compartments (Fig.13). They are 
persistently associated with the invariant chain Ii, which is poorly degraded in these cells (110, 
111) and thus prevents peptide loading. However, upon induction of maturation, Ii is degraded by 
cathepsin S and MHCII-peptide complexes are formed and transported to the surface (110). 
Additional mechanisms for the regulation of MHCII-peptide complex formation and presentation 
exist in DCs. First, internalized antigens are processed into peptides only once the cell starts to 
mature (112). Second, de novo MHCII synthesis is transiently upregulated during DC maturation 
(103, 104). Finally, the reduction in endocytosis slows down the recycling of the MHCII 
molecules at the cell surface and thus contributes to their increased half-life. 
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Figure 13. MHCII restricted antigen presentation. Exogenous antigens are derived from proteins that are 
endocytosed and processed by proteases. Newly synthesized MHCII molecules are retained in lysosomal 
compartments. Peptide loading occurs upon DC maturation in specialized antigen-processing vesicles, MIIC. The 
peptide-MHCII complexes are then externalized to the plasma membrane. 
 
In contrast to the model discussed above, exogenous antigens can also be presented by MHCI 
molecules, thereby leading to CD8+ T cell activation (114-116). This phenomenon is called cross-
presentation. It is crucial for the initiation of cytotoxic immune responses against antigens that 
are not synthesized by the DCs themselves, but by other cells. Normally, antigen-bearing cells do 
not directly initiate immune responses, since they are not capable of stimulating resting naive T 
cells. Most immune responses thus require antigen transfer to professional APCs, most probably 
DCs (160, 161), which then stimulate naive T cells. Apoptotic cells seem to be favorite targets 
for cross-presentation (161-163). Two intracellular pathways can result in cross-presentation: 
TAP-independent endocytotic or TAP-dependent ER MHCI peptide loading (164) (Fig.14). The 
latter implicates the existence of an endosome-to-cytosol transport system (165). 
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Figure 14. Cross presentation. a) Exogenous antigens can access MHCI molecules within endosomes that contain 
MHCI molecules that have been recycled from the membrane. b) Alternatively, antigen is transported from the 
endosome to the cytosol and processed similarly to endogenously derived antigens. 
 
2.3.5 T cell stimulation and tolerization by dendritic cells 
DCs have the unique ability to prime naïve CD4+ and CD8+ T cells. This has been shown in in 
vivo, in vitro and in situ experiments (166-175). In most cases, CD4+ T cell help is required for 
efficient CTL activation. In traditional models of CTL activation, the CD4+ and CD8+ T cells 
were thought to recognize antigen on the same APC. However, in the current model (176-178), 
the APCs are licensed to activate CTLs by T helper cells via upregulation of CD40 ligand 
(CD40L) on the DCs. Thus, a conditioned DC becomes a temporal bridge between a CD4+ T 
helper cell and a CTL. In addition to priming, DCs appear essential to maintain survival of naive 
CD4+ T cells (123) and immune T cell memory (179). Importantly, DCs are also involved in the 
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tolerization of the T cell repertoire to self-antigen. This occurs in the thymus (central tolerance) 
by deletion of developing T cells (123), and in lymphoid organs (peripheral tolerance) probably 
by the induction of anergy or deletion of mature T cells. 
DCs play apparently contradictory roles by stimulating as well as tolerizing T cells. This 
inconsistency may be attributed either to distinct DC lineages endowed with unique T cell 
stimulatory capacity or to a single DC type, which is instructed by environmental stimuli to 
perform different functions. Indeed, two major subtypes of DCs, that exhibit different functions, 
exist: myeloid and lymphoid (98). In addition, the different DC functions can be altered by the 
cytokine environment.  
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3 MATERIALS AND METHODS 
3.1 Preparation of monocytes and dendritic cells 
PBMCs were prepared from buffy coat fractions (Blood Transfusion Center, Geneva) by 
isolation over Ficoll-Paque (Pharmacia). Monocytes were obtained by adhesion of PBMCs in 10 
9cm tissue culture plates in RPMI 2% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM 
L-glutamine at 37°C for 1 hour. The non-adhering cells were removed by 4 washes and 
monocytes were incubated over night in RPMI 2% FCS, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin, 2 mM L-glutamine at 37°C. Contaminating B cells were depleted using anti-CD19 
antibody coupled magnetic beads (Dynal). The monocytes, > 90% pure as assessed by flow 
cytometry, were either cultured at 2x106 cells/ml in RPMI 10% FCS, 100 U/ml penicillin, 0.1 
mg/ml streptomycin, 2 mM L-glutamine supplemented with 2-mercaptoethanol (50 µM, Gibco) 
and 100 U/ml M-CSF (R&D Systems) or differentiated into DCs. For differentiation into DCs, 
the monocytes were cultured at 1,2x106 cells/ml in RPMI 10% FCS, 100 U/ml penicillin, 0.1 
mg/ml streptomycin, 2 mM L-glutamine supplemented with 2-mercaptoethanol (50 µM), GM-
CSF (600 U/ml, Leukomax, Essex Chemie AG) and IL-4 (750 U/ml, R&D Systems). Every 2 
days, half of the medium was replaced by fresh medium containing a two-fold concentration of 
cytokines. After 6 days of differentiation, the cells exhibited an immature DC phenotype (CD14-, 
CD1a+, MHCIIlow, CD86low, CD40low, CD80-, CD83-).  
DC maturation was induced by stimulating the immature DCs with LPS (from Salmonella 
abortus equi, 10 ng/ml, Sigma) for 24 to 48 hours. Mature DCs can be identified by high levels of 
surface MHCII, costimulatory molecules (CD86, CD80 and CD40) and the DC-restricted marker 
CD83. In certain experiments, DCs were stimulated with TNF-α (75 ng/ml, R&D systems), IFN-
α (1000 U/ml, kindly provided by C. Weissmann, Zürich) or IFN-γ (1000 U/ml, Life 
Technologies). For stimulation with CD40L, immature DCs were co-cultured at a ratio of 1:5 
with CD40L-expressing J558L cells (a gift from E. Padovan, Basel). For infection with 
Salmonella typhimurium (strain 14028 phoQ24), 5x106 cfu were added per 2.5x105 immature 
DCs and the mixture was incubated for 30 minutes at 37°C. Extracellular bacteria were then 
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killed by the addition of Gentamycin (50 µg/ml). For infection with Sendai (strain M, SeVM), the 
virus was added to immature DCs at a multiplicity of infection (MOI) of 20.  
Trichostatin A (TSA, Sigma) was co-administered with LPS at 100 ng/ml.  
 
3.2 Transduction of dendritic cells with lentiviral vectors 
Production of the HIV-derived vectors pseudotyped with the vesicular stomatitis virus (VSV)-
G envelope was achieved by transient co-transfection of three plasmids (see below) into the 293T 
cell line using calcium phosphate DNA precipitation. The supernatants containing viral particles 
were collected 48 hours after transfection, filtered through a 45 µm pore size filter, and 
concentrated by ultracentrifugation at 26’000 rpm for 90 minutes. The pellet was resuspended in 
1/100 volume of DMEM. Viral stocks were stored at –70°C and titers determined by transduction 
and FACS analysis (see below) of GFP expression in HeLa cells. Titers were usually between 
5x107 and 2x108 transducing units (TU) per ml. In addition, the integrated vector copies were 
quantified by real time PCR (see below) on genomic DNA isolated from transduced HeLa cells. 
A pair of probe and primers specific for the gag gene (present in the vector plasmid) was used 
together with a pair specific for mitochondrial DNA serving as an internal control. The HIV-
derived packaging construct used was pCMVR8.91, which encodes the HIV-1 Gag and Pol 
precursors as well as the regulatory proteins Tat and Rev (180). VSV-G was expressed from 
pMD.G. The HIV vector plasmid pWPTS (kindly provided by Didier Trono, Geneva) was a 
derivative of the original pHR’ backbone (181), with the following modifications. Self-
inactivating (SIN) vectors contain a deletion in the U3 region of the 3’ long terminal repeat 
(LTR) from nucleotide –418 to –18, removing all the transcriptionally active sequences (182). 
The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was inserted 
between the GFP gene and the 3’ LTR (183). A central polypurine tract was inserted upstream of 
the transgenic promoter to increase the nuclear import of the proviral DNA. The original pWPTS 
plasmid contained an EF-1α promoter derived from the pEF-BOS plasmid (184). The EF-1α 
promoter was either removed in order to create pWPTS-p0 or replaced by various CIITA 
promoter fragments to create pWPTS-pIII-322 (nucleotides -322 to +101 of pIII), pWPTS-pI-390 
(nucleotides –390 to +92 of pI), pWPTS-pI-1042 (nucleotides –1042 to +92 of pI), pWPTS-pI-
1987 (nucleotides –1987 to +92 of pI) and pWPTS-pI-2846 (nucleotides –2846 to +92 of pI).  
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106 human peripheral blood monocytes were transduced with lentiviral vectors at a MOI 
between 2 and 10. The following day, fresh medium containing GM-CSF and IL-4 was added 
and the cells were differentiated into immature DCs during 6 days and eventually induced for 
maturation with LPS as described above.  
 
3.3 Cell lines 
Raji (Burkitts’s lymphoma, EBV positive), RJ2.2.5 (CIITA deficient, derived from Raji), 
U937 (promonocyte), THP1 (promonocyte) and Me67.8 (melanoma) were grown in RPMI 10% 
FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine. HeLa and 293T were 
grown in DMEM 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine.  
RJ2.2.5 was transfected with an episomal expression vector containing a CIITA type I cDNA 
under the control of the SRα promoter. Transfected cells were selected with hygromycin for 10 
days and checked for cell surface MHCII expression by FACS. 
 
3.4 Embryonic stem cells 
E14.1 (129Sv) embryonic stem (ES) cells were cultured on gelatinized plates on a layer of 
irradiated feeder cells (SNL 76/7, (185)) in DMEM 20% FCS, 4 mM L-Glutamine, 1 mM Na-
Pyruvate, 0.1 mM non-essential amino acids, 100 µM 2-mercaptoethanol, 50 µg/ml gentamycin, 
2000 U/ml leukemia-inhibitory factor (LIF). ES cells were transfected by electroporation (3 µF, 
0.8 V) with 40 µg of the linearized targeting plasmid in 137 mM NaCl, 5 mM KCl, 0.7 mM 
Na2HPO4, 6 mM glucose, 28 mM 2-mercaptoethanol, 20 mM HEPES pH 7.0. G418-resistant 
clones were selected as described (186). Homologous recombinants were screened by PCR using 
a primer upstream of the 5’ end of the targeting construct (5’-GTGGGGTCAGTGTTGAC-3’) 
and an internal primer lying in the nitroreductase gene (5’-ATCTGCTCGGCCTGTTC-3’). 
Positive clones were confirmed by Southern blotting using EcoRI in combination with a 5’ 
external and a 3’ external probe (Fig.24, p.103). For deletion of the neo gene, one targeted ES 
cell clone was transfected with 40 µg of an expression plasmid coding for the Flp recombinase 
under the control of a CMV enhancer/β-actin promoter and the puromycin gene (kindly provided 
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by Francis Stewart, EMBL, Heidelberg). The transfected cells were selected with puromycin (1 
µg/ml) for three days. neo-deleted (G418 sensitive) clones were screened by PCR using a primer 
in the β-galactosidase gene (5’-GCAACTCTGGCTCACAG-3’) and a primer downstream of the 
neo gene (5’-TCCACTGTACACCTGAACAG-3’). Positive clones were confirmed by Southern 
blotting using PstI in combination with a probe downstream of the neo gene (Fig.25, p.104).  
 
3.5 Cytofluorometry 
250’000 cells were blocked with mouse IgG (2 mg/ml) prior to staining. Anti-human 
antibodies used were FITC conjugated anti-HLA-DR (clone G46-6, Pharmingen), anti-CD80 
(clone BB1, Pharmingen) and anti-CD40 (clone 5C3, Pharmingen); PE conjugated anti-CD1a 
(clone BL6, Immunotech), anti-CD83 (clone HB15a, Immunotech) and anti-CD86 (clone IT2.2, 
Pharmingen); and biotinylated anti-CD14 (clone UCHM1, Ancell) followed by Allophycocyanin-
conjugated Streptavidin (Pharmingen). Dead cells were excluded by loading with 7-
Aminoactinomycin D (Sigma). Staining with isotype matched antibodies was performed in 
parallel. 
 
3.6 RNA isolation  
Total RNA was prepared with Trizol (Life Technologies). 106 cells were lysed in 0.5 ml Trizol 
reagent for 5 minutes at room temperature and were eventually stored at –70°C until used. 100 µl 
chloroform was added. The samples were mixed vigorously and centrifuged for 15 minutes at 
12’000g at 4°C. The aqueous phase was transferred to a new tube and precipitated with 250 µl 
isopropanol and 5 µg glycogen. After centrifugation for 10 minutes at 12’000 g at 4°C, the pellet 
was washed with 75% ethanol and resuspended in 20 µl TE pH 7.5.  
 
3.7 RNase protection assay 
The RNA probes were generated under standard conditions by incubating 1 µg linearized 
plasmid with 75 µCi α32P-UTP in a final volume of 20 µl for 30 minutes at 37°C. After DNaseI 
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treatment for 15 minutes at 37°C, the probes were extracted, precipitated with ethanol and 
resuspended in FA buffer (90% formamide, 1 mM EDTA, xylene cyanol, bromophenol blue). 
They were purified on a 6% denaturing polypolyacrylamide gel and eluted in 200 µl 0.5 M 
NH4Ac, 0.1% SDS, 0.2 mg/ml tRNA in TE for 90 minutes at 4°C. The eluates were precipitated 
and resuspended at 500’000 cpm/µl in 80% formamid / 20% 5x HB (200 mM PIPES pH 6.4, 2 M 
NaCl, 5 mM EDTA). The probes were as follows: 
 
RPA probe description linearization transcription non-digested probe protected probe 
hCIITAI nu 107 exon1 –> 
nu 226 exon2 
XhoI T7 RNA 
polymerase 
399 nu 333 nu /         
226 nu (non-I) 
hCIITAIII nu 162 exon1 –> 
nu 226 exon2 
EcoRI T7 RNA 
polymerase 
454 nu 388 nu /         
226 nu (non-III) 
hCIITAIV nu 46 exon1 ->  
nu 226 exon2 
XhoI T7 RNA 
polymerase 
350 nu 272 nu /         
226 nu (non-IV) 
total 
hCIITA 
nu 1169 –> nu 
1361 
XhoI T7 RNA 
polymerase 
230 nu 193 nu 
HLA-DR nu 182 -> nu 
491 
HaeIII Sp6 RNA 
polymerase 
323 nu 309 nu 
hGAPDH nu 67 –> nu 166 EcoRI T7 RNA 
polymerase 
139 nu 100 nu 
 
2-10 µg RNA was mixed with 10 µl 5x HB, lyophilized and resuspended in H2O + total yeast 
RNA to obtain a final amount of 50 µg total RNA in 10 µl. 40 µl formamide was added, and 
samples were heated at 85°C for 5 minutes and incubated at 50°C over night. 350 µl RNase 
buffer (10 mM Tris pH 7.5, 0.3 M NaCl, 5 mM EDTA, 40 µg/ml RNase A, 6.7 U/ml RNase T1) 
was added, incubated at 30°C for 30 minutes and inactivated with 20 µl 10% SDS and 50 µg 
proteinase K for 15 minutes at 37°C. After extraction and ethanol precipitation, the samples were 
resuspended in 10 µl FA buffer, heated at 85°C for 5 minutes, run on a 6% denaturing 
polyacrylamide gel and visualized by autoradiography. The results were quantified by 
PhosphorImager analysis using the ImageQuant program.  
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3.8 Real time PCR and RT-PCR. 
cDNA was synthesized from total RNA using random hexamers and Superscript II reverse 
transcriptase (Life Technologies). 300 ng genomic DNA or cDNA from 40 ng of total RNA 
(supplemented with 0.8 µg yeast tRNA or 0.5 µg glycogen) was used per PCR reaction. Real 
time PCR was performed with the TaqMan sequence detection system (Applied Biosystems). 
Alternatively, the SYBR green method was used in certain experiments. The PrimerExpress 
software was used to design the primers and TaqMan probes for detection of mRNAs, non-
spliced nascent transcripts and genomic sequences. The sequences of the primers and probes are 
as follows.  
 
Name forward primer (5’-> 3’) reverse primer (5’-> 3’) probe (5’-> 3’) 
total CIITA CCTGCTGTTCGGGACCTA
AA 
GGATCCGCACCAGTTTG
G 
AGGGCCCAGCGCAAACT
CCAGT 
hCIITA I 
(spliced) 
CTAGAGAAAGGAGACCT
GGATTTG 
TCATAGAAGTGGTAGAG
GCACAGG 
CTGGAGCTTCTTAACAGC
GATGCTGACC 
hCIITA III 
(spliced) 
TGGGATTCCTACACAATG
CGT 
GGGTCAGCATCGCTGTTA
AGA 
CAGAGCCCCAAGGCAGC
TCACAGT 
hCIITA IV 
(spliced) 
CGGGGAACAGCGGCA TCATAGAAGTGGTAGAG
GCACAGG 
CTGGAGCTTCTTAACAGC
GATGCTGACC 
hCIITA I      
(non-spliced) 
GCCCCGGCCACAGTG TCCCATTGACTTCCCTTT
CAGA 
TGATTAAAAGTGATGCC
AACTTACCACCATGG 
hCIITA III   
(non-spliced) 
TGCTGGGTCCTACCTGTC
AGA 
CAGGACCAGCTGAGACT
GCAC 
CTTTCCCGGCCTTTTTAC
CTTGGGG 
HLA-DRA GCCAACCTGGAAATCAT
GACA 
AGGGCTGTTCGTGAGC
ACA 
CAACTATACTCCGATCAC
CAATGTACCTCCAGAG 
GFP CTGCTGCCCGACAACCA
C 
ACCATGTGATCGCGCTTC
TC 
CCAGTCCGCCCTGAGCA
AAGACC 
hGAPDH GAAGGTGAAGGTCGGAG
TC 
GAAGATGGTGATGGGAT
TTC 
CAAGCTTCCCGTTCTCAG
CC 
18S rRNA sequence unknown, purchased 
from Applied Biosystems 
  
gag GGAGCTAGAACGATTCG
CAGTTA 
GGTTGTAGCTGTCCCAGT
ATTTGTC 
ACAGCCTTCTGATGTTTC
TAACAGGCCAGG 
mito ACCCACTCCCTCTTAGCC
AATATT 
GTAGGGCTAGGCCCACC
G 
CTAGTCTTTGCCGCCTGC
GAAGCA 
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Samples were quantified using relative standard curves for each amplification. All results were 
normalized with respect to the internal control, and expressed relative to the levels found in 
immature DCs. 
 
3.9 Measurement of CIITA mRNA stability 
Immature DCs or DCs stimulated with LPS for 2.5 hours were supplemented with 50 µM 5,6-
dichloro-1-β-ribofuranosyl benzamidazole (DRB, Sigma) for 0, 1, 2, 3 and 4 hours. Total RNA 
was then prepared and the remaining CIITA mRNA was quantified by real time RT-PCR.  
 
3.10 Isolation of nascent RNAs 
107 cells were washed 3 times with cold PBS and resuspended in 1 cell volume HB 0.3 (0.3 M 
sucrose, 10% glycerol, 60 mM KCl, 15 mM NaCl, 15 mM HEPES pH 7.9, 0.5 mM EDTA, 0.15 
mM Spermine, 0.5 mM Spermidine). 1 cell volume HB 0.3 supplemented with 0.8% NP40 was 
added, gently mixed and incubated on ice for 10 minutes. The lysed cells were layered over 600 
µl HB 0.9 (same as HB 0.3 but containing 0.9 M sucrose) and centrifuged for 10 minutes at 
1500g at 4°C. The pellet was resuspended in 400 µl NSB (20 mM Tris pH 7.9, 75 mM NaCl, 0.5 
mM EDTA, 50% glycerol, 0.85 mM DTT, 0.125 mM PMSF, 0.1 mg/ml tRNA). After addition of 
3 ml nuclear lysis buffer ( 20 mM HEPES pH 7.6, 0.3 M NaCl, 1 M urea, 7.5 mM CaCl2, 0.2 
mM EDTA, 1 mM DTT, 1% NP-40, 0.1 mg/ml tRNA) and incubation on ice for 10 minutes, the 
samples were centrifuged for 10 minutes at 15’000 g at 4°C. The supernatant containing the free 
nuclear transcripts was supplemented with SDS to 0.1% final, extracted, ethanol precipitated and 
resuspended in 50 µl 10 mM Tris pH 7.5. The chromatin pellets containing the nascent transcripts 
were resuspended in 2 ml chromatin buffer (50 mM NaAc pH 5, 50 mM NaCl, 0.5% SDS, 0.1 
mg/ml tRNA), extracted 3 times with hot phenol (non buffered and supplemented with 1/10 
volume of supplement mix (50 mM NaAc pH 5, 50 mM NaCl)). The NaCl concentration was 
adjusted to 0.15 M and the samples were ethanol precipitated and resuspended in 50 µl 10 mM 
Tris pH 7.5. The free nuclear RNAs and the nascent transcripts were treated with RNase-free 
DNaseI (Roche), reverse transcribed and analyzed by real time RT-PCR. 
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 3.11 In vivo genomic footprinting 
107 cells were resuspended in 10 ml RPMI containing 0.1% DMS and incubated for 10 
minutes at 37°C. The cells were washed 3 times and resuspended in 1.5 ml harvest buffer (1 mM 
Tris pH 7.5, 0.4 M NaCl, 2 mM EDTA, 0.2% SDS, 0.2 mg/ml proteinase K). After 3 hours of 
incubation at 37°C, the lysate was extracted and precipitated with 1/2 volume NH4Ac 7.5 M and 
1/2 volume isopropanol. The pellet was resuspended in 1 ml H2O, precipitated with 1/10 volume 
NaAc 3 M and 3 volumes ethanol and resuspended in 200 µl H2O. The in vitro treated DNA was 
isolated as described above except that the incubation in 0.1% DMS was omitted. The DMS 
treatment was instead performed after the second precipitation by adding 0.9 µl DMS to the DNA 
and incubating for 30 seconds at room temperature. In vivo and in vitro treated samples were then 
precipitated with 50 µl ice-cooled stop buffer ( 1.5 M NaAc pH 7, 1 M 2-mercaptoethanol, 0.1 
mg/ml tRNA) and 750 µl ethanol. The genomic DNAs were cut at the DMS-modified G 
nucleotides by incubation in 200 µl 1 M piperidine for 30 minutes at 90°C followed by 
lyophylization. The samples were resuspended in 200 µl H2O and precipitated twice with 1/10 
volume NaAc 3 M and 2.5 volumes ethanol.  
The ligation-mediated PCR (LM-PCR) was done with Vent DNA polymerase (New England 
Biolabs) for all steps. For the first extension, 1-2 µg DNA were mixed with 6 µl 1st strand buffer 
5x (200 mM NaCl, 50 mM Tris pH 8.9, 25 mM MgSO4, 0.05% gelatine), 1 µl primer 1 0.3 µM, 1 
µl dNTP 6.25 µM and 0.5 U Vent polymerase in a final volume of 30 µl. The following cycle 
was performed: 5 minutes at 95°C, 30 minutes at Tm+2°C, 10 minutes at 76°C. 20 µl ligation 
solution (110 mM Tris pH 7.5, 18 mM MgCl2, 50 mM DTT, 0.0125% BSA), 15.5 µl ligation mix 
(10 mM MgCl2, 20 mM DTT, 3 mM ATP, 0.005% BSA), 5 µl annealed linker (20 µM in 250 
mM Tris pH 7.7) and 4.5 µl T4 DNA ligase (1 U/µl) were added. After over night incubation at 
16°C, the samples were precipitated with 10 µg tRNA, 1/10 volume NaAc 3 M and 2.5 volumes 
ethanol and resuspended in 71 µl H2O. For amplification by PCR, 20 µl vent buffer 5x (200 mM 
NaCl, 100 mM Tris pH 8.9, 25 mM MgSO4, 0,045% gelatine, 0.45% Triton X-100), 3.2 µl dNTP 
6.25 mM, 1 µl primer 2 (10 µM), 1 µl linker 1 (10 µM) and 1 U vent polymerase were added and 
the following cycle was performed: 5 minutes at 95°C, then 25 cycles with 1 minute at 95°C, 2 
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minutes at Tm+2°C, 1 minute at 73°C. For the last extension, 1 µl vent buffer 5x, 1.6 µl dNTP 
6.25 mM, 2 µl primer 3 (labeled with γ32P-ATP, 3 µM) and 1 U vent polymerase were added and 
extended for 5 minutes at 95°C, 2 minutes at Tm+2°C, 10 minutes at 76°C. The reaction was 
stopped by the addition of 295 ml stop mix ( 10 mM Tris pH 7.5, 260 mM NaAc, 4 mM EDTA, 
20 µg tRNA), extracted and precipitated. The samples were resuspended in 20 µl formamide 
loading buffer, run on a sequencing gel and visualized by autoradiography. 
 
primer pair primer 1 (5’ -> 3’) primer 2 (5’ -> 3’) primer 3 (5’ -> 3’) 
hCIITA pI forward ATTGGCTCCAACAGA
AGGCTG 
CAGAAGGCTGTGGGC
TTCTCTG 
TGGGCTTCTCTGGCAC
ATGCACCTG 
hCIITA pI reverse CTGGCCAGTGCCTGGA
ATC 
GTGCCTGGAATCTCCG
CTCAC 
TCCGCTCACCCAGCAT
GCAGCATC 
hCIITA pIII reverse AGAAGCACACAGCCT
CATCACTA 
CACTAGCCTCATCACT
AACCAGTCA 
TAACCAGTCACCAGTT
GGGAGCCCG 
linker 1 GCGGTGACCCGGGAG
ATCTGAATTC 
  
linker 2 GAATTCAGATC   
 
3.12 Protein extracts 
20x106 cells were chilled on ice, washed twice with cold PBS and resuspended in two cell 
volumes of X-400 buffer (50 mM HEPES pH 7.9, 400 mM KCl, 1 mM EDTA, 1 mM EGTA, 
20% glycerol, 2 mM DTT, 1x CompleteTM, 5 µg/ml leupeptin, 1 mM PMSF, 0.5 mM NaF, 0.5 
mM Na3VO4). After three cycles of snap-freezing in liquid nitrogen and thawing on ice, the 
extracts were cleared by centrifugation. The extract concentration was determined using the 
Bradford method. 
 
3.13 Immunoprecipitation and immunoblotting 
For immunoprecipitation, 5 µg α-CIITA-C antibody (specific for the C-terminal part of 
CIITA) was covalently coupled with dimethyl pimelinediimidate (DMP, Fluka) in 0.2 M sodium 
borate pH 9.0 to 32 µl protein-A Sepharose beads. The coupling was stopped by addition of 
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glacial acetic acid and quenched in 0.2 M ethanolamine pH 8.0. After three washes with storage 
buffer (1x PBS , 0.01% merthiolate, 1 µg/ml BSA), the coupled antibody was stored in this same 
buffer.  
800 µg extract (corresponding to 5x106 cells) was mixed with 1 volume dilution buffer (20 
mM HEPES pH 7.9, 0.1 M EDTA, 0.01% NP-40, 1 mM DTT, 1x CompleteTM) and cleared by 
centrifugation. The coupled α-CIITA-C antibody was washed in dilution buffer and added to the 
cleared extract. After 3 hours of incubation with end-over-end rotation at 4°C, the beads were 
washed 3 times with washing buffer (20 mM HEPES pH 7.9, 10% glycerol, 1 mM EDTA, 0.01% 
NP-40, 100 mM KCl). The precipitated proteins were then eluted in 11 µl elution buffer (20 mM 
Tris pH 6.8, 6% glycerol, 2.5% SDS) by incubation at 90°C for 2 minutes. The supernatant was 
supplemented with 1,2 µl of a mix containing 40% 2-mercaptoethanol, 0.3 M KCl and 0.2% 
bromphenolblue. The samples were denatured for 2 minutes at 90°C and separated by SDS-
PAGE (3.9% stacking and 8% resolving gel).  
The proteins were transferred to a PVDF membrane (ImmobiolonTM-P, Millipore) using a 
semi-dry transfer cell (Biorad). The membrane was rinsed in TBS-T (100 mM Tris pH 7.9, 0.9% 
NaCl, 0.1% Tween-20) and blocked in 1% blocking buffer (Roche) over night at 4°C. The α-
CIITA-N antibody (specific for the N-terminus of CIITA) diluted 1000 times in 0.5% blocking 
buffer was added and incubated for 1 hour at room temperature. After 1 wash in TBS-T and 3 
washes in 1% milk in TBS-T for 5 minutes each, the secondary antibody coupled to POD 
(horseradish peroxidase) diluted 2000 times in 0.5% blocking buffer was added and incubated for 
30 minutes at room temperature. The membrane was then washed for 5 minutes in TBS-T and for 
10 minutes in 1% milk in TBS-T. Revelation was done with Lumi-Light Western Blotting 
substrate (Roche). 
 
3.14 Chromatin immunoprecipitation and quantification 
40x106 cells were fixed in 40 ml PBS supplemented with 1% formaldehyde, 10 mM NaCl, 5 
mM HEPES pH 7.9 for 8 minutes at room temperature. The fixation was stopped by the addition 
of glycine to a final concentration of 0.18 M. The cells were then washed in cold PBS and stored 
at –70°C. For isolation of the chromatin, the cell pellet was resuspended in TE containing 1 mM 
PMSF, 5 mM benzamidine, 1 µg/ml leupeptine, 5 µg/ml aprotinin and 0.5% NP-40 and 
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centrifuged for 5 minutes at 2’500 rpm. The pellet was then resuspended in 50 ml TE containing 
1 mM PMSF, 5 mM benzamidine, 1 µg/ml leupeptine, 5 µg/ml aprotinin, 1% Triton X-100, 0.5% 
Na-deoxycolate and 0.5 M NaCl. After another centrifugation, the pellet was washed in PBS and 
stored at –70°C. For sonication, the chromatin were resuspended in 1.5 ml TEN (10 mM Tris pH 
8.0, 1 mM EDTA, 0.1 M NaCl) and fragmented 12 times for 15 seconds at maximal power. After 
clearing by centrifugation, the chromatin was stored at –70°C. The size of the sonicated 
fragments and the concentration of the chromatin were estimated on a 1% agarose gel after 
reversing the crosslink (see below). 
4 µg chromatin per immunoprecipitation reaction were diluted with 5 volumes of 
dilution/incubation buffer (20 mM HEPES pH 7.9, 0.2 M NaCl, 2 mM EDTA, 0.1% Na-
deoxycolate, 0.1% SDS ,200 µg/µl herring sperm DNA, 1 mg/ml BSA, 1x CompleteTM) and 
cleared by centrifugation. The supernatant was added to protein A Sepharose CL-4B beads (20 µl 
per reaction) and incubated for 30 minutes with end-over-end rotation at room temperature. The 
supernatant was then collected, cleared by centrifugation and diluted with 650 µl 
dilution/incubation buffer. After addition of the antibodies (specific for acetylated histones H3 
and H4 (Upstate Biotechnology) and pre-immune serum), the reactions were incubated at 4°C 
over night with very slow end-over-end rotation. The immunoprecipitations were then cleared by 
centrifugation, added to protein A Sepharose beads (12 µl per reaction) in 400 µl 
dilution/incubation buffer and incubated for 1 hour at room temperature with medium-fast end-
over-end rotation. 7 washes were performed with the following buffers: wash 1 and 2: 20 mM 
HEPES pH 7.9, 0.2 M NaCl, 2 mM EDTA, 0.1% Na-deoxycolate, 0.1% SDS; wash 3 and 4: 20 
mM HEPES pH 7.9, 0.5 M NaCl, 2 mM EDTA, 0.1% Na-deoxycolate, 0.1% SDS; wash 5 and 6: 
20 mM Tris pH 8.0, 0.25 M LiCl, 2 mM EDTA, 0.5% NP-40, 0.5% Na-deoxycolate; wash 7: TE 
supplemented with 0.1% NP-40. After the last wash, 500 µl elution buffer (111 mM Tris pH 8.0, 
1.11% SDS) were added and incubated at 65°C for 10 minutes. At this step, a chromatin sample 
(4 µg, “total standard”), that has not been immunoprecipitated, was included and treated as the 
immunoprecipitated reactions. 14 µl proteinase K (10 mg/ml) and 11 µl NaCl (5 M) were added. 
After centrifugation of the samples, the supernatant was retrieved and incubated at 42°C for 2 
hours and at 67°C over night to reverse the crosslink. The samples were then extracted, 
precipitated with 20 µg glycogen, 66 µl NaAc (3 M, pH 5.1) and 920 µl isopropanol and 
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resuspended in 50 µl TE plus 50 µl sample dilution buffer (0.25x TE, 30 mM NaCl, 0.2 mg/ml 
glycogen).  
The immunoprecipitated DNA fragments were amplified by PCR and analyzed on 4% agarose 
gels or quantified with the SYBR green real time PCR method (Applied Biosystems). The 
primers for each amplicon were as follows. 
 
primer forward (5’ -> 3’) reverse (5’ -> 3’) 
A (pI-1.5kb) CCCCAGCTGAGAGATGGTAATC GCACAAAACAGAGGATTTGCATAG 
B (pI-0kb) AAAAGCCAATATCCATCCGTTC GCATCCAAAACATGAAGTGAAAAC 
C (pII-3.7kb) CCAGGCTGCTTGCGAAC TGCATTTCAGAAGGAGATGGAAT 
D (pII-0kb) TGGGGCCCCAGACAATATC GCCCATGTGCCAGTTCAAC 
E (pIII-3kb) TCCTGGCTGGGTACCACTG CTCTGAGCAGAGCAAGTGACATC 
F (pIII-0kb) AGAAACAGAAATCTGACCGCTTG TCATCACTAACCAGTCACCAGTTG 
G (pIV-0kb) CCACTGTGAGGAACCGACTG TGGAGCAACCAAGCACCTAC 
DRA  ATTTTTCTGATTGGCCAAAGAGTAATT AAAAGAAAAGAGAATGTGGGGTGTAA 
GAPDH CCCGGCTACTAGCGGTTTTAC CTGCGGGCTCAATTTATAGAAAC 
 
3.15 Yeast-two-hybrid screening 
The yeast-two-hybrid screen was performed with the DupLEX-A™ system (OriGene). The 
303 base pair fragment coding for the N-terminal extension of the 132 kD CIITA isoform were 
cloned into the two bait plasmids pEG202 (selectable marker HIS3, C-terminal fusion) and 
pNLexA (selectable marker HIS3, N-terminal fusion). Yeast strain EGY48 (MATα trp1 his3 
ura3 leu2::6 LexAop-LEU2) was transformed with either pEG202-CIITA and the reporter 
plasmid pJK103 (selectable marker URA3, 2 LexAop-lacZ, medium sensitivity) or pNLexA-
CIITA and the reporter plasmid pSH18-34 (selectable marker URA3, 8 LexAop-lacZ, high 
sensitivity) according to standard protocols (187). The resulting parental strains were tested for 
autoactivation by the bait of the lacZ and the LEU2 reporter genes. For monitoring lacZ 
expression, the yeast cells were plated on selective media supplemented with 80 µg/ml X-gal and 
the color of the colonies was observed. For monitoring LEU2 expression, yeast colonies were 
tested for growth on leucine-selective plates. The parental strains were transformed with a cDNA 
library derived from a human B cell line and cloned into the pRS314 vector (selectable marker 
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TRP1) downstream of a VP16 activation domain and under the control of a galactose inducible 
promoter (188). The transformants were grown over night at 30°C in glucose selective medium. 
After centrifugation, the cells were resuspended in galactose selective medium and incubated 
over night at 30°C to induce expression of the library. Transformants were then plated on 
galactose selective plates lacking leucine. The cDNA expression plasmids were rescued from 
potential positive transformants according to standard protocols and sequenced. 
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4 RESULTS 
Parts of the results obtained during this thesis have been the subject of a publication. This 
publication constitutes the first part of the results chapter of this thesis. In addition, some non-
published results are included. 
 
4.1 Expression and promoter usage of the MHC2TA gene in dendritic cells 
4.1.1 Publication 
“Maturation of Dendritic cells Is Accompanied by Rapid Transcriptional Silencing of Class 
II Transactivator (CIITA) Expression”  
Salomé Landmann, Annick Mühlethaler-Mottet, Luca Bernasconi, Tobias Suter, Jean-Marc 
Waldburger, Krzysztof Masternak, Jean-François Arrighi, Conrad Hauser, Adriano Fontana and 
Walter Reith.  
Journal of Experimental Medecine (2001), 194 (4): 379-391. 
 
Summary 
Cell surface expression of MHCII molecules is increased during the maturation of DCs. In 
contrast to the increased cell surface MHCII expression, de novo biosynthesis of MHCII mRNA 
is turned off during DC maturation. This paper shows that this is due to a remarkably rapid 
reduction in the synthesis of class II transactivator (CIITA) mRNA and protein. This reduction in 
CIITA expression occurs in human monocyte-derived DCs and mouse bone marrow-derived 
DCs, and is triggered by a variety of different maturation stimuli, including LPS, TNF-α, CD40 
ligand, IFN-α, and infection with Salmonella typhimurium or Sendai virus. It is also observed in 
vivo in splenic DCs in acute myelin oligodendrocyte glycoprotein induced experimental 
autoimmune encephalitis. The arrest in CIITA expression is the result of a transcriptional 
inactivation of the MHC2TA gene. This is mediated by a global repression mechanism 
implicating histone deacetylation over a large domain spanning the entire MHC2TA regulatory 
region. 
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4.1.2 Expression of CIITA during the differentiation of monocytes into dendritic cells 
Immature human monocyte-derived DCs express high levels of CIITA mRNA. CIITA type I 
and type III mRNAs are represented at similar levels, whereas type IV mRNAs are scarcely 
detectable (Fig.3 in the publication, p.88[384]). 
We were interested to determine how CIITA expression is regulated during the differentiation 
of human monocytes into DCs. RNA was thus isolated from monocytes and immature DCs and 
all types of CIITA mRNA were quantified by RNase protection. Monocytes were found to 
express about ten times less total CIITA mRNA than immature DCs. In contrast to immature 
DCs, CIITA type III mRNA is the only type expressed at significant levels in monocytes. Type I 
and type IV mRNAs are both expressed very weakly or not at all in these cells (Fig.15A). In a 
time course analysis of the differentiation from monocytes into immature DCs over six days, a 
progressive increase of type I and type III CIITA mRNA expression was observed (Fig.15B). The 
time course for type I and type III mRNA induction is similar. 
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Figure 15. CIITA expression during the differentiation from monocytes into immature DCs. A. Expression of 
all three types of CIITA mRNA was analyzed by RNase protection and quantified by PosphoImager in monocytes 
and immature DCs. The results are standardized with respect to endogenous GAPDH mRNA. B. The expression of 
CIITA type I and type III mRNA was quantified by real time RT-PCR during the differentiation of monocytes into 
immature DCs (day 0 to day 6). The values are normalized with respect to 18S rRNA and are given as the percentage 
relative to the levels found in immature DCs (day 6). 
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4.1.3 Occupation of the CIITA type I promoter in monocytes and immature dendritic cells 
CIITA type I mRNA expression is strongly induced during the differentiation of monocytes 
into immature DCs, most likely as the result of activation of transcription. Changes in 
transcriptional activity are frequently reflected by alterations in promoter occupation that can be 
visualized in living cells by means of in vivo genomic footprint experiments (189). We thus used 
this technique to study whether the differentiation of monocytes into immature DCs is 
accompanied by modifications in the occupation of CIITA pI. The region that was analyzed is 
situated immediately upstream of the transcription initiation site of pI and contains a short 120 
base pair sequence displaying a high degree of homology between the human and the mouse 
gene.  
The footprints found in immature DCs were mostly the same in monocytes (Fig.16, residues –
41, -86 and –90 in the lower strand and residues –49 and –118 in the upper strand). In addition, 
guanine residues –33 and –75 in the upper strand are occupied in monocytes, but not in immature 
DCs. It may be speculated that proteins bound to these residues could be transcriptional 
repressors that bind to pI in monocytes and are released during the differentiation into DCs. The 
existence and identity of such factors requires further investigations. 
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Figure 16. Differences in occupation of CIITA pI in monocytes and immature DCs. The occupation of pI in 
monocytes and immature DCs was analyzed by in vivo genomic footprinting. The first and second lane in each panel 
show the pattern obtained for monocytes and immature DCs, respectively. The third lane in each panel shows the 
pattern obtained in vitro with naked control DNA. Open arrowheads represent residues occupied in monocytes and 
immature DCs, filled arrowheads represent residues occupied in monocytes only.  The bent arrow indicates the site 
of transcription initiation. 
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 4.1.4 CIITA pI is not responsive to IFN-γ in human peripheral monocytes  
Mouse peritoneal macrophages express high levels of CIITA type I mRNA after exposure to 
IFN-γ (85). They do so in both the presence and absence of a functional pIV. This represents the 
first, and up to now unique, example of pI activation in response to IFN-γ.  
In order to determine whether cells of the human monocyte/macrophage lineage display a 
similar pI usage in response to IFN-γ, we analyzed human peripheral blood monocytes after 
activation with IFN-γ. Interestingly, the situation is different in human and mouse cells. Human 
monocytes strongly upregulate CIITA pIV (and slightly pIII) after exposure to 1000 U/ml IFN-γ 
for 48 hours (Fig.17). However, CIITA pI stays at uninduced levels. 
CIITA promoter usage may thus be regulated in a species-specific manner. An alternative 
explanation for the above observations may be that the peritoneal macrophages used in the mouse 
experiments and the peripheral blood monocytes used in the human experiments are not of the 
same sublineage and can thus not be compared in their respective responsiveness to IFN-γ.  
0
1
2
3
4
5
6
7
8
9
10
CIITA I CIITA III CIITA IV total CIITA
mono
mono + IFN-g
 
Figure 17. CIITA expression of human monocytes in response to IFN-γ. Human peripheral blood monocytes 
were stimulated with 1000 U/ml IFN-γ for 48 hours or left untreated, and total RNA was isolated. The different 
CIITA mRNA types were analyzed by real time RT-PCR. The values are normalized with respect to 18S rRNA and 
are given as the fold induction. 
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4.2 Molecular dissection of CIITA promoter I 
4.2.1 Introduction 
Immature DCs express high levels of CIITA. Similar quantities of  CIITA type I and type III 
transcripts are detectable (Fig.3 in the publication, p.88[384]). The mechanisms controlling the 
expression of these two types of CIITA in immature DCs are so far unknown. In vivo genomic 
footprint experiments have revealed occupations in the proximal region of pI within or near 
sequence motifs representing potential binding sites for known transcription factors (Fig.7 in the 
publication, p.88[387]). However, none of these motifs or the factors binding to them have been 
confirmed by functional studies. Concerning pIII, cis-regulatory elements and several factors 
binding to them have been identified in B cells (190), in which pIII is highly expressed. 
However, the role of these sequence elements and factors in immature DCs is not clear. In vivo 
genomic footprint patterns of pIII look similar in B cells and immature DCs (190) (Fig.7 in the 
publication, p.88[387]).  
We have now investigated the regulation of pI and to a lesser extent of pIII in immature DCs. 
Different fragments of pI were fused to a reporter gene. To test the activity of these constructs it 
was necessary to develop a gene transfer system that could introduce exogenous DNA efficiently 
into DCs. 
 
4.2.2 Gene transfer into dendritic cells 
Primary DCs cannot be transfected easily by classical gene transfer technologies. We have 
thus developed a transduction system with lentiviral vectors. Lentiviral vectors allow efficient 
transduction of non-dividing cells and stable integration of the transgene into the genome. DCs 
can be transduced efficiently with human immunodeficiency virus (HIV)-based vectors (191-
193) (Fig.18A). The currently available vectors are optimized in terms of biosafety requirements 
and efficiency of transgene expression. They contain a 400 base pair deletion in the 3’ long 
terminal repeat (LTR) leading to self-inactivation (SIN) (182). The deletion, which includes the 
TATA box, abolishes LTR promoter activity and thus allows transgenes to be expressed from 
tissue-specific or regulated promoters. Transduction of immature DCs with lentiviral vectors does 
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not lead to maturation of these cells as demonstrated by comparing the expression levels of the 
maturation marker CD83 before and after transduction (Fig 18B). 
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Figure 18. Transduction of human monocyte-derived DCs with lentiviral vectors. A. Immature DCs were 
transduced with a lentiviral vector expressing GFP under the control of the EF1α promoter at an MOI of 0, 0.6, 3 and 
6. Six days after transduction, GFP expression (fl1) was analyzed by FACS. B. Transduced and non-transduced DCs 
were analyzed by FACS for expression of the maturation marker CD83 (fl2). 
 
4.2.3 The first 390 base pairs of pI are sufficient for transcriptional activity in immature DCs 
To define the functional regions of pI, we constructed a series of progressive 5’ deletions of pI 
fused to the GFP reporter gene in the lentiviral vector plasmid pWPTS (Fig.19D). All constructs 
contained the first 92 base pairs of the 5’ untranslated sequence of CIITA type I. Immature DCs 
were transduced with the lentiviral vectors and GFP expression was analyzed by FACS. The 
shortest construct containing only 390 base pairs of the promoter (pI-390) displayed significant 
GFP expression (Fig.19A). Additional upstream sequences spanning 1042, 1987 and 2846 base 
pairs of pI (pI-1042, pI-1987 and pI-2846) did not further enhance transcriptional activity, but 
rather reduced it (Fig.19A). The activity of the different promoter fragments was also analyzed at 
the mRNA level. Total RNA was isolated from the transduced DCs and GFP mRNA levels were 
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quantified by real time RT-PCR (Fig.19B). The relative quantities of GFP transcripts correlated 
well with the levels of GFP proteins detected at the cell surface. In order to verify that the 
reduced level of activity of the pI-1042, pI-1987 and pI-2846 constructs was not due to an 
unwanted splicing event affecting the integrity of the promoter fragments, we checked their 
integrity in the transduced cells by southern blot analysis. As shown in Fig 19C, all promoter 
fragments were of the expected length and should thus be functional. 
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Figure 19. The first 390 base pairs of pI are sufficient for transcriptional activity in immature DCs. A. Four pI 
fragments of different length (pI-390, pI-1042, pI-1987 and pI-2846) were fused to the GFP reporter gene in the 
lentiviral vector plasmid pWPTS. Immature DCs were transduced with the vectors and GFP expression was analyzed 
by FACS six days after transduction. The mean fluorescence intensity is indicated for each sample. n.t., non-
transduced. B. Total RNA was isolated from the transduced cells described in A. and GFP mRNA was quantified by 
real time RT-PCR. The values are normalized with respect to GAPDH mRNA. C. The integrity of the different 
promoter fragments was checked by Southern blot analysis. Genomic DNA was isolated from HeLa cells transduced 
with the vectors described in A. and digested with the enzyme AccI. The probe hybridized to fragments of 1394 base 
pairs (pI-390), 2046 base pairs (pI-1042), 2991 base pairs (pI-1987) and 3850 base pairs (pI-2846). D. Scheme of the 
pWPTS vector plasmid and the different pI promoter fragments. The restriction sites for cloning (ClaI, BamHI, SalI) 
and for southern blot analysis (AccI) are indicated. 
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In a subsequent set of experiments, the transcriptional activity of the pI-390 promoter 
fragment was compared to several other promoters. The promoter fragment in the pWPTS vector 
plasmid was either removed in order to obtain a negative control vector lacking a promoter (p0) 
or was replaced by the promoter of the elongation factor EF-1α (EF-1α) gene which displays a 
strong activity in immature DCs (194). In addition, a pWPTS vector plasmid containing the first 
322 base pairs of pIII, which has been shown to be sufficient for activity in B cells, was 
constructed (pIII-322). Immature DCs transduced with the vector containing the EF-1α promoter 
expressed GFP at high levels (Fig.20A).  
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Figure 20. pI-390 displays a weaker transcriptional activity than EF-1α. A. Immature DCs were transduced with 
lentiviral vectors expressing GFP under the control of pI-390, pIII-322 or EF-1α. Non-specific background 
expression was monitored with the p0 construct lacking any promoter. Transduced cells were analyzed for GFP 
expression by FACS. The mean fluorescence intensity is indicated for each sample. n.t., non-transduced. B. Total 
RNA was isolated from the transduced cells in A. and GFP mRNA was quantified by real time RT-PCR. The values 
are normalized with respect to GAPDH mRNA. 
 
The transcriptional activities of pIII-322 and pI-390 were much weaker than the one of EF-1α, 
but they were both clearly above the background of p0. Expression driven by pIII-322 was 
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slightly higher than for pI-390 (Fig.20A). These results were confirmed by measuring GFP 
expression at the mRNA level (Fig.20B). As in the previous experiment, the GFP mRNA levels 
agree well with the GFP levels observed at the cell surface. The relatively high mRNA 
background observed with p0 is most probably due to some transcription initiation events from 
sites in and around the 5’ LTR giving rise to functional and non-functional transcripts which 
cannot be discriminated by our RT-PCR measurement. 
 
4.2.4 The minimal promoter region pI-390 is specific for cells of myeloid origin 
In order to define the cell type specificity of the pI-390 promoter fragment, we tested its 
activity in different cell types, namely in two epithelial cell lines (HeLa, 293T), in a melanoma 
cell line (Me67.8), in a B cell line (Raji) and in two promonocytic cell lines (U937, THP1) 
(Fig.21). The level of background GFP expression (in the cells transduced with the p0 vector) 
varied from one cell type to another. This may be explained by a strong cell type dependence of 
transcription initiation from cryptic promoter sequences in and around the 5’ LTR. GFP 
expression levels from p0 were therefore accepted as background for each cell type. The pI-390 
promoter fragment proved to be silent in HeLa, 293T, Me67.8 and Raji cell lines. However, it 
displayed some transcriptional activity in the promonocytic cell lines U937 and THP1. It may 
thus be speculated that pI-390 expression is not absolutely restricted to DCs but may instead be 
specific for cells of the myeloid lineage such as monocytes and monocyte-derived DCs. 
Surprisingly, the pIII-322 promoter fragment displays a high transcriptional activity not only in 
immature DCs and the B cell line Raji but in all cell types tested. This finding contrasts with the 
results of earlier studies in which the pIII-322 promoter fragment was analyzed in a transitory 
transfection system and found to be inactive in the Me67.8 melanoma cell line (82).  
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Figure 21. pI-390 is specifically active in myeloid cells. Immature DCs and HeLa, 293T, Me67.8, Raji, U937 and 
THP1 cells lines were transduced with lentiviral vectors encoding the GFP reporter gene under the control of the 
promoters p0, pI-390, pIII-322 and EF-1α. GFP expression was analyzed by FACS six days after transduction. The 
mean fluorescence intensity is indicated for each sample. n.t., non-transduced.  
 
4.2.5 The transcriptional activity of pI-390 does not change with DC maturation 
Expression of endogenous CIITA in DCs is rapidly silenced upon induction of maturation 
(Fig.3 in the publication, p.88[384]). The mechanism responsible for this silencing appears to 
involve a global repression of the entire regulatory region of the MHC2TA gene (Fig.8 in the 
publication, p.88[388]). Sequences and factors controlling the silencing have not been identified 
so far. It can thus not be excluded that the proximal promoter regions are involved. In order to 
test this, we analyzed the activity of the minimal promoter regions of pI and pIII during 
maturation of DCs. Immature DCs were transduced with the lentiviral vectors encoding GFP 
under the control of pI-390, pIII-322 or the control promoters p0 and EF-1α. The cells were 
either left untreated or induced to mature with LPS and GFP expression was then analyzed by 
FACS. As expected, the activity of the EF-1α promoter, as well as the background activity of p0, 
were not influenced by maturation of DCs (Fig.22A). GFP expression levels driven by pI-390 
and pIII-322 did also not change during maturation (Fig.22A). To confirm these findings we 
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analyzed GFP expression at the mRNA level and did again not find any difference between 
immature and mature DCs (Fig.22B). Due to the likely implication of a global silencing 
mechanism of pI and pIII during DC maturation, it is not unexpected that repression cannot be 
seen with the minimal promoter fragments. Potential regulatory elements involved in repression 
may lie far upstream or downstream of the transcription initiation sites.  
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Figure 22. The activities of pI-390 and pIII-322 are not influenced by maturation of DCs. A. Immature DCs 
were transduced with lentiviral vectors encoding GFP under the control of p0, pI-390, pIII-322 or EF-1α as 
described. Cells were then either left untreated (left column) or induced to mature with 10 ng/ml LPS for 48 hours 
(right column). GFP surface expression was analyzed by FACS. n.t., non-transduced. B. Total RNA was isolated 
from the cells in A. and GFP mRNA was quantified by real time RT-PCR. The values are normalized with respect to 
GAPDH mRNA. 
 
A potential repression of pI-390 and pIII-322 during DC maturation could have been masked 
in the previous experiment because of the long half-life of the GFP protein (> 24 hours). A short-
lived GFP variant (d4GFP) with a half-life of only four hours also exists. In order to try to reveal 
a possible repression of pI-390 and pIII-322 during DC maturation, we replaced the long-lived 
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GFP in our lentiviral vector plasmids with the d4GFP variant and transduced immature DCs with 
the modified vectors. Expression of d4GFP from the EF-1α promoter was weak in both immature 
and mature DCs (Fig.23). d4GFP was scarcely detectable when placed under the control of pI-
390 or pIII-322 and no difference in d4GFP expression could be seen between immature and 
mature DCs (Fig.23). The short-lived d4GFP reporter gene is thus not suitable for the analysis of 
the weak pI-390 and pIII-322 promoters. 
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Figure 23. The short-lived d4GFP is too weak for our system. The usual long-lived GFP was replaced in all 
lentiviral vector plasmids with the short-lived variant d4GFP. Immature DCs were transduced and either left 
untreated (left column) or induced for maturation with 10 ng/ml LPS for 48 hours (right column). d4GFP expression 
was analyzed by FACS. 
 
4.2.6 Summary 
We have used a lentiviral gene transfer system to perform reporter gene experiments with 
CIITA promoter I. We could show that a short 390 base pair fragment (pI-390) is sufficient for 
expression of the GFP reporter in immature DCs. Larger promoter fragments containing 
additional upstream sequences did not further enhance the transcriptional activity of pI-390, but 
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rather reduced it. Such an effect of large promoter fragments is frequently observed in reporter 
gene assays and is not easily explained. The upstream sequences may for instance contain some 
repression elements that inhibit promoter activity. pI-390 is a relatively weak promoter compared 
to the minimal promoter region of CIITA pIII (pIII-322) or the EF-1α promoter. However, pI-
390 activity is clearly above the background expression of the promoter-less construct p0. pI-390 
is transcriptionaly active in two promonocytic cell lines in addition to monocyte-derived DCs. It 
thus displays specificity for cells of myeloid origin rather than a strict DC specificity. It should be 
interesting to challenge this hypothesis by testing the activity of pI-390 in primary monocytes and 
macrophages. We could further show that pI-390 activity is not influenced by maturation of the 
DCs.  
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4.3 CIITA pI knockout mice 
Expression of the MHC2TA gene is controlled by a complex regulatory region containing the 
three independent promoters pI, pIII and pIV (Fig.8, p.41). In the past, several in vitro studies 
have established the specificities of these promoters. pI drives constitutive expression in DCs, 
pIII does so in B cells and in certain types of human DCs, while pIV is activated by IFN-γ in 
other cell types. Recently, pIV knockout mice have been generated (85). They have contributed 
largely to our current understanding of the complicated regulation of CIITA expression. Deletion 
of pIV selectively abrogates IFN-γ-induced MHCII expression in non-bone marrow-derived cells 
and constitutive MHCII expression in cTECs. However, MHCII expression is unaffected in bone 
marrow-derived APCs, including DCs, B cells, and IFN-γ-activated cells of the macrophage 
lineage. Macrophages have been found to activate CIITA expression mainly by means of pI (85). 
In addition, a recent study shows that in wild type mice, macrophages use both, pI and pIV, for 
CIITA expression in response to IFN-γ (195). pIV activity declines after a short period of time (6 
hours), whereas pI stays active up to 72 hours after IFN-γ stimulation. 
Inspired by these new findings on pI in mice and because of the important role of pI for CIITA 
expression in DCs, we decided to investigate further the role and specificity of pI in vivo. We 
decided to tackle this by the generation of pI knockout mice using the gene targeting method 
(196, 197). The targeting construct was designed to replace the coding region of CIITA exon I by 
a loxP-flanked nitroreductase (NTR) gene, a β-galactosidase (lacZ) gene and a frt-flanked neo 
gene (Fig.24A). The E.coli NTR converts the prodrug CB1954 ((5-aziridin-1-yl)-2,4-dinitro-
benzamide) into a cytotoxic DNA interstrand cross-linking agent leading to DNA crosslinking 
and DNA strand breakage (198). It thus allows rapid and selective killing of the cells that express 
NTR, in our case cells that express pI, primarily DCs. Mice devoid of DCs represent an 
interesting and new tool to study the importance of this cell type under normal conditions and 
during the course of infections. They may be strongly affected in their capacity to activate their 
adaptive immune system. NTR-mediated inducible cell ablation offers a number of advantages 
over the use of HSV1 thymidine kinase for the selective killing of cells in vivo. The former does 
not require cell proliferation, displays only little bystander activity and does not lead to male 
sterility. The NTR gene can be excised by means of Cre recombinase, which recognizes the loxP 
sites flanking the NTR gene in our targeting construct. Excision of the NTR gene allows 
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expression of the downstream lacZ from pI. The lacZ gene serves to determine the pI expression 
pattern in vivo. lacZ expression can be visualized by in situ staining or by flow cytometry using 
the substrate di-β-D-galactopyranoside (FDG) (199). The neo gene present in the targeting 
construct is under the control of the PGK promoter and serves for selection of clones that have 
integrated the targeting construct. It can be deleted by Flp-mediated recombination to ensure that 
the in vivo pattern of pI activity is not perturbed. 
ES cells were culture as described in the materials and methods section. ES cell clones in 
which the targeting construct was integrated by homologous recombination were isolated by a 
PCR strategy and the presence of the mutated locus was confirmed by Southern blot experiments 
(Fig.24B).  
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Figure 24. Generation of heterozygous Mhc2ta pI knockout ES cells. A. The regulatory region of the wild type 
Mhc2ta locus, the targeting construct and the targeted locus are depicted. Exons I and III are represented by open 
boxes, loxP and frt sites by filled triangles. The EcoRI sites (RI) and probes used for Southern blotting are indicated. 
B. The blots for three positive (19, 31 and 148, encircled) and one negative (151) ES cell clones probed with the 
5’probe (left) and 3’ probe (right) are shown. Both probes hybridize to a 12.3 kb fragment in the wild type locus. In 
the targeted locus, the 5’ probe hybridizes to a 3.5 kb fragment and the 3’ probe to an 8.5 kb fragment. 
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The neo gene was deleted in the positive ES cell clone 148 by transfecting it with a Flp 
expression vector (Fig.25A). neo-deleted clones were identified by a PCR strategy and confirmed 
by Southern blot experiments (Fig.25B). The clones in which the neo gene was deleted have been 
amplified and the cells are currently being injected into blastocysts in collaboration with the 
group of Ari Waisman in Cologne. 
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Figure 25. Flp-mediated deletion of the targeted locus. A. The regulatory region of the wild type Mhc2ta locus, 
the targeted locus and the neo-deleted locus are depicted. Exons I and III are represented by open boxes, loxP and frt 
sites by filled triangles. The PstI sites and the probe used for Southern blotting are indicated. B. The blot for four 
clones in which the neo gene was deleted (148.1, 148.23, 148.40 and 148.56, encircled) and five clones in which the 
neo gene was not deleted (148.4, 148.7, 148.14, 148.15 and 148.18) is shown. The probe hybridizes to a 3.5 kb 
fragment in the wild type locus, to a 3.9 kb fragment in the targeted locus and to a 12.2 kb fragment in the deleted 
locus. 
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4.4 Interaction partners of the N-terminus of dendritic cell-specific CIITA 
As a consequence of the existence of three different CIITA promoters, there are three CIITA 
isoforms differing in their N-terminus (Fig.8, p.41). The largest 132 kD isoform, which is mainly 
expressed in DCs, results from initiation at the first AUG initiation codon in the CIITA type I 
mRNA. It contains a 101 amino acid N-terminal extension not present in the other isoforms and 
shows enhanced capacity to activate MHCII transcription compared to the other CIITA isoforms 
(200) (Luc Otten, unpublished results). In addition, the 132 kD isoform seems to have an 
extremely short half-life (our unpublished observations). It is likely that these features are due to 
an intrinsic property of the N-terminus unique to this CIITA isoform. We were thus interested in 
investigating the role, structure and function of this N-terminal extension. A yeast-two-hybrid 
approach was chosen to find possible interaction partners. This method allows the identification 
of proteins that can bind to a protein of interest.  
The N-terminal 101 amino acids of the 132 kD CIITA isoform (bait) were fused to the 
bacterial LexA DNA binding domain. The VP16 activation domain was placed upstream of a 
human B cell cDNA library controlled by the inducible GAL1 promoter. Two independent 
reporter genes were used: the β-galactosidase gene under the control of two LexA operator sites 
and the chromosomal LEU2 gene under the control of six LexA operator sites. 3x107 independent 
yeast transformants were screened for expression of the LEU2 gene. 140 LEU2 positive colonies 
were selected and tested for expression of the β-galactosidase gene. The cDNA expression 
plasmids were recovered from 13 strong blue colonies and transformed back into the parental 
strains. Four of them could be confirmed in a second round of selection. Three out of the four 
clones interact strongly with the bait and contain the same 2.24 kb insert coding for a guanine 
nucleotide-exchange protein (p200, BIG1) (201-203). The fourth clone interacts only weakly 
with the bait and contains a 0.54 kb insert coding for a homologue of the mouse WW domain 
binding protein 3 (204). Interestingly, the mutation L27Q of the bait, which was found to reduce 
the transactivation potential of CIITA type I (compared to the wild type protein) in mammalian 
cells (200), abolishes the interaction with all of the four clones isolated in the yeast system. 
The BIG1 guanine nucleotide exchange protein (202, 203) catalyzes the replacement of GDP 
with GTP on ADP-ribosylation factors (ARFs), which play an important role in intracellular 
vesicular trafficking. BIG1 is expressed ubiquitously in eukaryotes and localizes to the Golgi 
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apparatus (203). It contains a Sec7 domain, which confers sensitivity to the drug brefeldin A 
(205). However, it is not clear how BIG1 interacts with the N-terminal extension of the 132 kD 
CIITA isoform and what the role of this interaction could be. The WW domain binding protein 3 
is a novel protein containing a proline-rich region including the motif PPLP (204). It was isolated 
as a ligand of the WW domain of the formin-binding protein 11 (204). Several WW domain 
containing proteins have been localized in the nucleus and have been documented to participate 
in co-activation of transcription and modulation of RNA polymerase II activity (206). The precise 
link between proteins containing a WW domain, WW domain binding proteins and CIITA awaits 
further investigation. The N-terminus of CIITA itself however does not contain a WW domain. 
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5 DISCUSSION : CONCLUSIONS AND PERSPECTIVES 
CIITA is the master regulator of MHCII expression. The work presented in this thesis has shed 
light on how CIITA controls MHCII expression in DCs. In particular, it describes the constitutive 
expression of CIITA type I and type III in immature DCs and the rapid transcriptional silencing 
of the CIITA gene during DC maturation. Furthermore, the generation of CIITA pI knockout 
mice was initiated. This discussion focuses on the non-published results. The published results 
have been extensively discussed in the publication and only some aspects will be addressed again 
here. 
 
5.1 CIITA silencing in dendritic cells during maturation 
Cell surface expression of MHCII molecules is increased during DC maturation, while de 
novo biosynthesis is turned off. We have shown that the reduction in MHCII synthesis is due to 
silencing of the MHC2TA gene during DC maturation. Reduction of CIITA expression was 
observed in response to a variety of different DC maturation stimuli as well as in vivo in splenic 
DCs during MOG induced EAE. Our results demonstrate further that inactivation of the 
MHC2TA gene during DC maturation is mediated by a global repression mechanism implicating 
histone deacetylation over a large domain. 
The changes in CIITA levels during the course of EAE are remarkable (Fig.4D in the 
publication, p.88[385]). CIITA expression is at least 20 times lower in purified splenic DCs from 
EAE mice as compared to normal mice. All three types of CIITA (I, III and IV) are affected. 
CIITA type I is however most relevant because it is the only type to be expressed at high levels in 
immature mouse DCs. The almost complete extinction of CIITA expression in splenic DCs of 
EAE mice suggests that the entire DC population is induced to maturate. Immunization of mice 
with MOG in adjuvant triggers a massive systemic inflammation. One may expect that the 
observed CIITA shutdown and DC maturation are consequences of the systemic inflammation 
rather than a specific response to MOG immunization. It will be very interesting to compare the 
situation observed in EAE with other inflammatory and autoimmune diseases (i.e. lupus or 
arteriosclerosis). During minor local inflammations, not enough DCs may be activated and 
matured to detect any CIITA reduction in response to DC maturation in the population of total 
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splenic DCs. Progress in understanding the role of DCs in the course of MOG-induced EAE 
should be made by the detailed characterization of splenic DCs from EAE mice. DCs are a 
heterogeneous population and at least three DC subpopulations have been identified in the mouse 
spleen (207). They differ in their phenotype, localization and function. Lymphoid CD4-CD8+ 
DCs reside in the T cell areas of the periarterial lymphoid sheath (PALS), whereas myeloid 
CD4+CD8- and CD4-CD8- DCs are present in the marginal zones. CD8+ CDs tend to induce a 
Th1-biased T cell response, whereas CD8- DCs tend to induce a Th2-biased response (208-210). 
In addition, CD8+ DCs were reported to induce tolerization (211). However, this conflicts with 
their role in promoting Th1 responses. The characterization of the phenotype of the DCs from 
EAE mice will possibly give some indications on their function, be it immunogenic or 
tolerogenic. Interestingly, recent papers have reported that some tolerogenic subtypes of DCs are 
able to prevent or relieve of EAE (212-214). 
Along with transcriptional inactivation of the MHC2TA gene, a large regulatory region is 
deacetylated in mature DCs (Fig.8B and C in the publication, p.88[388]). The region extending 
from 1.5 kb upstream of pI down to pIV (15 kb) has been analyzed in two to three kb intervals. It 
will be interesting to investigate how large the deacetylated region is. Does it cover the coding 
region of MHC2TA ? How far does it extend upstream of pI ? The boundaries of the deacetylated 
region and fluctuations in the acetylation levels may give some hints on the control of 
deacetylation and the repression mechanism.  
Almost 40 years ago, histone deacetylation was already correlated with transcriptional 
repression (215). Under normal conditions, up to 13 of the 30 lysine residues in the tails of the 
core histones are acetylated (216). This steady-state level of acetylation is maintained by the 
opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) (217, 
218). It is believed that targeting of HATs and HDACs to promoter regions creates specific 
patterns of hyper- and hypoacetylation in a background of global acetylation that correlates with 
transcription activation and repression, respectively (219, 220). How does histone acetylation 
regulate transcription of specific genes ? Although histone acetylation does not disrupt individual 
nucleosomes, moderate levels of acetylation can destabilize the higher order folding of 
nucleosomal arrays (221), and the acetylation of specific lysine residues can regulate the 
chromatin binding or enzymatic activity of other nonhistone-proteins (222-224). Many HATs and 
HDACs controlling the acetylation state of chromatin have been identified. They always seem to 
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act as a part of large complexes. They are unable to access their histone substrates unless they are 
targeted there by DNA bound activators or repressors. Recently, it has been recognized that 
different HDACs deacetylate preferentially very specific lysine residues in different chromatin 
regions (225). Some have diverse promoters as their targets whereas others are specialized for 
heterochromatin or ribosomal DNA. There is thus only a small degree of functional overlap 
among different HDACs. It should be interesting to try to determine which HDACs and HATs 
are implicated in modulating the acetylation status of the MHC2TA gene in DCs. 
Acetylation is not the only type of covalent modification found in histones. Histone tails can 
also be methylated, phosphorylated and ubiquitinated. Methylation occurs on different lysine and 
arginine residues of histone H3 and H4 and the transcriptional consequences can be either 
negative or positive. Methylation of lysine 4 (H3) and arginine 17 (H3) for instance are linked to 
gene activation (226, 227), whereas methylation of lysine 9 (H3) results in gene repression (228). 
Numerous methyltransferases targeting specific lysine or arginine residues have been identified 
so far. When all possible histone modifications are taken into account, one can hypothesize that 
certain combinations of modifications in one or more histone tails act sequentially or 
concomitantly to form a histone code (229, 230). Different patterns of modifications correlate 
with specific transcriptional states. An inactive state can for instance be characterized by 
deacetylation at lysine 14 (H3), which precedes methylation of lysine 9 (H3). Further work in our 
system should attempt to establish the histone modification code at the MHC2TA gene in 
immature DCs, and how it changes during DC maturation. 
In summary, our knowledge on histone modifications and transcription regulation is growing 
constantly. The increasing number of known histone modifications and histone modifying 
enzymes provides new tools and should allow us to characterize further the mechanism leading to 
silencing of the MHC2TA gene during DC maturation. First, the exact lysine residues that are 
deacetylated need to be identified. Chromatin immunoprecipitation experiments using antibodies 
specific for single acetyllysine residues should be helpful. When histone methylation and 
eventually phosphorylation and ubiquitination are also taken into account, an entire pattern of 
histone modifications may be recognized. This should then allow us to identify the corresponding 
HDACs and histone methyltransferases involved in the repression process and eventually to 
situate them in the context of the signal transduction events involved in DC maturation. 
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5.2 MHC2TA promoter usage 
Expression of CIITA is controlled by three alternative promoters (Fig.8, p.xx). They are used 
differentially in a cell type specific and inducible manner. According to the classical model, pI is 
active constitutively in DCs, pIII is used in B cells and pIV is inducible by IFN-γ. Recent results 
have changed this view of promoter usage to some extent. Monocytes and macrophages use pI in 
addition to pIV for IFN-γ induced CIITA expression (85). Differences in the kinetics of pI versus 
pIV CIITA expression induced by IFN-γ could be evidenced (195). Similar levels of CIITA type 
I and type IV are present after six hours of IFN-γ stimulation. However, after 72 hours of 
exposure to IFN-γ, CIITA type IV declines while CIITA type I remains constant. Consistent with 
this, mice lacking pIV don’t lose IFN-γ inducible CIITA expression in monocytes and 
macrophages, but selectively abrogate it in non-hematopoietic cells. A modified model of 
promoter usage may thus be proposed (Fig.8, p.41). Cells of myeloid origin (DCs, monocytes, 
macrophages) require pI for constitutive or IFN-γ induced CIITA expression. Constitutive CIITA 
expression in cells of lymphoid origin (B cells, T cells) is driven by pIII. Finally, pIV is 
indispensable for expression in non-hematopoietic cells (fibroblasts, astrocytes, cTECs). Some 
species-specific differences have also been recognized. In humans, pI does not respond to IFN-γ, 
either in monocytes or in monocyte-derived DCs (Fig.5D of the publication, p.88[385] ; Fig.17 
p.92). In addition, human monocyte-derived DCs express not only CIITA type I but also type III 
(Fig.3 in the publication, p.88[384]), while mouse DCs use essentially only pI. The promoter 
usage in other human DC subtypes, for instance in plasmocytoid DCs or thymic DCs, has not yet 
been studied.  
In order to confirm and refine our current knowledge about CIITA promoter usage, we have 
initiated the project of creating pI knockout mice. These mice should lack CIITA, and thus 
MHCII, expression on their DCs. It is not clear however, if all DC subtypes will be equally 
affected. If thymic DCs lack MHCII expression in the pI knockout mice, negative selection of 
thymocytes will most likely be strongly impaired leading to a strong susceptibility for 
autoimmune diseases. Furthermore, it is an open question how monocytes and macrophages will 
respond to IFN-γ in these mice. What will be the consequences of the changed MHCII expression 
for the induction of primary immune responses ?  
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The pI knockout mice were designed such that the first exon of CIITA type I will be replaced 
by the NTR gene. NTR will thus be expressed in all cells in which pI is active, most likely DCs. 
These cells will be killed selectively after administration of the prodrug CB1954. Mice devoid of 
DCs should represent an interesting and new tool to assess the physiological role of DCs in the 
immune response and in thymocyte differentiation. They should also help to understand the 
consequences of DC dysfunction. The NTR gene in the pI knockout mice will be flanked by loxP 
sites and can thus be eliminated by means of the Cre recombinase. This will lead to pI-driven 
expression of the lacZ gene, which was introduced downstream of the loxP-flanked NTR gene. 
Expression of lacZ under the control of pI should help to identify all cell types that express pI in 
vivo under normal or pathological conditions.  
Identification of the alternative CIITA promoters raises the question of whether the three 
resulting CIITA transcripts and protein isoforms have different functions. Each of the three 
CIITA transcripts has a different 5’ end (Fig.8, p.41). They give rise to three protein isoforms, 
each possessing a different N-terminus. The role of the different N-terminal extensions is not yet 
understood. The extension of the 132 kD isoform resulting from the CIITA type I transcript 
consists of 101 N-terminal amino acids. It may confer an enhanced transactivation capacity to the 
132 kD isoform compared to the other two isoforms (200) (Luc Otten, unpublished results). 
However, this hypothesis awaits further experimental support. Our attempt to identify interaction 
partners of the 101 amino acid N-terminal extension by means of a yeast-two-hybrid screen 
resulted in the isolation of two candidates, a guanine nucleotide-exchange protein and a 
homologue of the mouse WW domain binding protein 3. The relevance of these two proteins and 
their interaction with CIITA are not yet clear. The new technique of RNA interference (RNAi) 
should be suitable for analyzing their role in CIITA mediated MHCII transcription. RNAi is a 
process of sequence-specific post-transcriptional gene silencing in animals and plants. It is 
initiated by a double-stranded RNA that is homologous in sequence to the silenced gene. The 
mediators of this process are 21 to 22 nucleotide small interfering RNA (siRNA) duplexes that 
cause efficient and specific downregulation of gene expression, resulting in functional 
inactivation of the targeted genes. Targeting siRNAs to the candidate genes isolated in our yeast-
two-hybrid system should give important clues concerning the relevance and role of these genes 
in modulating the activity of CIITA.  
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5.3 Molecular dissection of CIITA promoter I 
The regulatory mechanisms controlling two of the three CIITA promoters (pIII and pIV) have 
been addressed several years ago (82, 86, 190). In this respect, pI is a straggler. The molecular 
analysis of pI has been severely hampered by the necessity of working with primary DCs, which 
are difficult to obtain in large numbers and to transfect by classical transfection methods. Stable 
DC cell lines have been established (231-234), but they are not suitable because they either do 
not express significant levels of CIITA and MHCII, or do not respond to maturation stimuli as 
primary DCs do. We therefore decided to investigate the regulation of pI in primary DCs by 
means of a lentiviral transduction system. Lentiviral vectors allow very efficient transduction of 
non-dividing cells. However, the production of the vectors is variable in efficiency and very time-
consuming.  
We have determined the minimal promoter region of pI, which encompasses 390 base pairs. 
Compared to EF-1α, pI-390 is a rather weak promoter. Its activity is also only about half of that 
of the minimal promoter region of pIII, pIII-322. The activity of pI-390 is restricted to DCs and 
promonocytic cell lines. However, its activity in primary monocytes and macrophages remains to 
be determined. It is thus possible that pI-390 expression is more specific for DCs in vivo than 
suggested by our reporter gene experiments.  
Due to its restricted expression, pI-390 attracts attention with regards to possible applications 
in the field of immunotherapy. DCs represent an ideal adjuvant for immunization against 
pathogens or tumor antigens. The availability of a DC-specific promoter offers great advantages 
over constitutive promoters. It ensures DC-specific expression of the antigen even if a 
heterogeneous population of cells (containing DCs or DC precursors) is transduced, such that 
isolation of pure DCs is not required. In the context of immunotherapy it is worth mentioning that 
the activity of pI-390 does not change during the maturation of DCs. This allows the constitutive 
supply and presentation of antigen, which should assist the induction of potent CTL responses 
and protective immunity.  
Our genomic footprint experiments (Fig.7 in the publication, p.88[387] ; Fig.16, p.91) have 
pinpointed a number of sites in pI that are occupied in DCs in vivo. This represents a strong 
indication that these sequences constitute important cis-acting regulatory elements for the activity 
of pI in DCs. Another indication of important promoter regions is generally provided by the 
 112 
presence of sites that display strong homology between different species. In the case of pI, the 
sites that are occupied in the in vivo footprint experiments do not always match the most 
conserved stretches of sequence. It will thus be a good idea to mutate both types of sequences, the 
occupied and the conserved ones, in the context of pI-390 in order to analyze their role in the 
regulation of pI. These experiments may be performed with the recently developed nucleofection 
technology (235) instead of the lentiviral transduction system. Nucleofection is an improvement 
of the classical electroporation technology and allows highly efficient and non-viral transient 
transfection of primary cells. DCs have been transfected this way with an efficiency of over 50% 
(data not shown). The mutated pI-390 promoter fragments can be fused to the luciferase reporter 
gene and thus be analyzed by a classical luciferase assay. This method is highly quantitative and 
appropriate for the comparison of different promoter mutants. Once relevant cis-acting regulatory 
elements have been identified, the task of identifying the transcription factors that bind to these 
sequences will have to be tackled.  
 
In conclusion, this thesis has contributed to our understanding of the mechanism controlling 
MHCII biosynthesis in immature and mature DCs. In particular, it provides insights into the role 
of the master regulator CIITA during DC maturation. Furthermore, the regulation of the DC-
specific CIITA promoter was investigated. The results have opened interesting perspectives for 
anti-tumor immunotherapy and vaccination.  
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6 ABBREVIATIONS 
APC antigen presenting cell 
ARF adenosine 5’-diphosphate ribosylation factor 
ATP adenosine 5’-triphosphate 
β2m β2-microglobulin 
BIG1 Brefeldin A-inhibited guanine nucleotide-exchange protein 
Blimp-1 B lymphocyte-induced maturation protein-1 
BLS Bare Lymphocyte Syndrome 
BMT bone marrow transplantation 
bp base pair(s) 
BSA bovine serum albumin 
cAMP cyclic adenosine 5’-monophosphate 
CARD caspase recruitment domains 
CB1954 (5-aziridin-1-yl)-2,4-dinitro-benzamide 
CBP CREB binding protein 
CD cluster of differentiation 
CD40L CD40 ligand 
cDNA complementary DNA 
cfu colony forming units 
CIITA class II transactivator 
CLIP class II associated Ii peptide 
CMH-I complexe majeur d’hisocompatibilité de classe I 
CMH-II complexe majeur d’hisocompatibilité de classe II 
CMV cytomegalovirus 
cpm counts per minute 
CRE cAMP response element 
CREB CRE binding protein 
cTECs cortical thymic epithelial cells 
CTL cytotoxic T lymphocytes 
d4GFP GFP with a half-life of 4 hours 
DBD DNA binding domain 
DCs dendritic cells 
DE aspartic acid, glutamic acids 
DMEM Dulbecco Modified Eagle’s Medium 
DMP dimethyl pimelinediimidate 
DMS dimethyl sulfate 
DNA deoxyribonucleic acid 
DNaseI deoxyribonuclease I 
dNTP deoxynucleotide triphosphate 
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DRB 5,6-dichloro-1-β-ribofuranosyl benzamidazole 
DTT DL-dithiothreitol 
EAE experimental autoimmune encephalitis 
EBV Eppstein Barr virus 
EDTA ethylenediaminetetraacetic acid 
EF elongation factor 
EGTA ethylene glycol-bis (β-aminoethyl ether) 
ER endoplasmatic reticulum 
ES (cell) embryonic stem (cell) 
FACS fluoresence-activated cell sorting 
FcR receptor for Fc portion of immunoglobulins 
FCS fetal calf serum 
FDG di-β-D-galactopyranoside 
FITC fluorescein isothiocyanate 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GDP guanosine 5’-diphosphate 
GFP green fluorescent protein 
GM-CSF granulocyte macrophage colony stimulating factor 
GTF general transcription factor 
GTP guanosine 5’-triphosphate 
H3 histone 3 
H4 histone 4 
HAT histone acetyltransferase 
HDAC histone deacetylase 
HEPES N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HIV human immunodeficiency virus 
HLA human leucocyte antigen 
HSC human stem cell 
IFN interferon 
IgG immunoglobulin G 
Ii invariant chain 
IL interleukin 
IRF interferon regulatory factor 
ISRE interferon-stimulated response element  
JAK Janus family of protein tyrosine kinases 
kb kilobase 
lacZ β-galactosidase 
LIF leukemia inhibitory factor 
LM-PCR linker-mediated PCR 
LPS lipopolysaccharide 
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LRR leucine rich repeat 
LTR long terminal repeat 
µCi micro-Curie 
M-CSF macrophage colony stimulating factor 
mg milligram 
µg microgram 
MHC major histocompatibility complex 
MHC2TA major histocompatibility complex class II transactivator 
MHCI major histocompatibility complex class I 
MHCII major histocompatibility complex class II 
MIIC MHCII compartment 
ml milliliter 
µl microliter 
MOI multiplicity of infection 
mRNA messenger RNA 
NES nuclear export signal 
NF-Y nuclear factor Y 
NK natural killer (cell) 
NLS nuclear localization signal 
NP-40 nonidet P-40 
NTR nitroreductase 
nu nucleotide 
P proline 
PALS periarterial lymphoid sheath 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PGE prostaglandin E 
PGK phosphoglycerin kinase 
pI CIITA promoter I 
pIII CIITA promoter III 
pIV CIITA promoter IV 
PIPES 1,4-piperazinediethane sulfonic acid 
PKA protein kinase A 
PMSF phenylmethylsulfonylfluoride 
POD horseradish peroxidase 
PRDI-BF1 positive regulatory domain I binding factor-1 
PST proline, serine, threonine 
pTEFb positive transcription elongation factor b 
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PVDF poly (vinylidene chloride) 
Q glutamine  
RFX regulatory factor X 
RNA ribonucleic acid 
RNAi RNA interpherence 
RNase ribonuclease 
RPA RNase protection assay 
rpm rotations per minute 
RPMI tissue culture medium developed by the Roswell Park Memorial Institute 
rRNA ribosomal RNA 
RT-PCR reverse transcription polymerase chain reaction 
SDS lauryl sulphate sodium salt 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SeV Sendai virus 
SIN self-inactivating / self-inactivation 
siRNA small interfering RNA 
SOCS-1 suppressor of cytokine signaling-1 
STAT signal transducer and activator of transcription 
TAF TBP-associated factor 
TAP transporter associated with antigen processing 
TCR T cell receptor 
TE Tris-EDTA buffer 
TFII transcription factor involved in Pol II transcription 
Tm melting temperature 
TNF tumor necrosis factor 
Tris tris(hydroxymethyl)aminomethane 
tRNA transfer RNA 
TSA trichostatin A 
TU transducing unit 
USF-1 upstream regulatory factor 1 
UTP uridine 5’-triphospate 
VSV vesicular stomatitis virus 
WPRE woodchuck hepatitis virus posttranscriptional regulatory element 
X-gal 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside 
X2BP X2 binding protein 
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